

New Process

The present invention relates to new processes for improving the manufacture of clavams e.g. clavulanic acid. The present invention also provides novel DNA sequences and new microorganisms capable of producing increased amounts of clavulanic acid.

Microorganisms, in particular *Streptomyces sp.* produce a number of antibiotics including clavulanic acid and other clavams, cephalosporins, polyketides, cephamycins, tunicamycin, holomycin and penicillins. There is considerable interest in being able to manipulate the absolute and relative amounts of these antibiotics produced by the microorganism and accordingly there have been a large number of studies investigating the metabolic and genetic mechanisms of the biosynthetic pathways (Demain, A.L. (1990) "Biosynthesis and regulation of β -lactam antibiotics." in "50 years of Penicillin applications, history and trends").

Streptomyces clavuligerus produces two major groups of antibiotics; one being the cephamycins, cephalosporins and penicillins (Demain, A.L. (1990) *supra*) and the other comprising clavams. Clavams can be arbitrarily divided into two groups, 5S and 5R clavams, dependent on their ring stereochemistry. The commercially important clavam clavulanic acid, a component of the antibiotic Augmentin (trade mark of GlaxoSmithKline), is a 5R clavam. Examples of 5S clavams are clavam-2-carboxylate (C-2-C), 2-hydroxymethyl clavam (2HMC) and alanylclavam (Brown *et al.* (1979) J. Chem. Soc. Chem. pp282-283).

Genes encoding biosynthetic enzymes and regulatory proteins for clavulanic acid production have been located in a cluster next to the genes involved in cephamycin C production and make up a supercluster of antibiotic related genes within the *S. clavuligerus* genome (Alexander *et al.* (1998) J.Bacteriol. 180:4068-79). For example the genes encoding the enzymes involved in clavaminic acid production, a clavulanic acid precursor, which include *orf2* (*ceaS*) (Khaleeli *et al.* (1999) J. Am. Chem. Soc. 121:9223-9224), *orf3* (*bls*) (Bachmann and Townsend (1998) Chem. Commun.:2325-2326), *orf4* (*pah*) (Wu *et al.* (1995) J. Bacteriol. 177:3714-3720), *orf5* (*cas2*) (Marsh *et al.* (1992) Biochemistry. 31:12648-57) and perhaps *orf6* (Kershaw *et al.* (2002) Eur. J. Biochem. 269,2052-2059) are all located within the clavulanic acid cluster. Disruptions in *orfs2-6* cause a complete loss of clavulanic acid production when mutant cultures are grown on starch asparagine medium (Aidoo, K.A. *et al.* (1993) p219-236 In. V.P. Gullo, J.C. Hunter-Cevera, R. Cooper and R. K. Johnson (ed.), Developments in Industrial Microbiology series, vol.33 Society for Industrial Microbiology, Fredericksburg, Va.). However this loss is conditional upon the growth media used for when mutants are grown on Soy medium (Salowe *et al.* (1990) Biochemistry 29: 6499-6508) clavulanic acid production is partially restored (Jensen *et al.* (2002) Antimicrob. Agents and Chemother. 44: 720-726). This phenomenon could suggest that other genes present in the *S.*

clavuligerus genome could compensate in some way for the loss of the activity of these genes under certain conditions. Alternatively it could be that the Soy media contains very small amounts one or more of the metabolites produced by the *orfs* 2-6 allowing strains disrupted in these genes to make small amounts of clavulanic acid.

5 Marsh *et al.* (1992) *supra* has reported that *S. clavuligerus* contains two copies of the *cas* gene (*cas1* and *cas2*). *cas1* is not associated with the clavulanic acid gene cluster and has a high homology to *cas2*. Disruption of *cas2* decreases clavulanic acid production by 35% when cultures are grown on Soy medium and eliminates production entirely when cultures are grown on starch asparagine (SA) medium (Paradkar and Jensen 1995 J.Bact 177: 1307-
10 1314). The disruption of the *cas1* gene results in mutants which produce near wild type levels of clavulanic acid on SA medium, but produce 31-73% less clavulanic acid when grown on Soy medium than the wild type (Mosher et al (1999) Antimicrob. Agents and Chemother. 43: 1215-1224). It is also reported that in mutant strains where both the *cas1* and *cas2* genes have been disrupted no clavulanic acid is produced under any of the fermentation conditions tested.
15 Interestingly when the genes surrounding *cas1* were sequenced, no additional genes involved in clavulanic acid production were found but instead six novel genes involved in 5S clavam biosynthesis (named *cvm1* to 6) were identified. (Mosher et al (1999) *supra*). Further work on these 5S clavam-specific genes showed that disruption of the genes, using genetic engineering methodologies, leads to improvements in the levels of clavulanic acid made by
20 the mutant strains and also dramatic reductions in the levels of 5S clavam production (WO98/33896). This reduction in 5S clavam production, in particular the 5S clavam clavam-2-carboxylate, is especially important in the commercial production of clavulanic acid because some 5S clavams are known to be toxic and for this reason the levels are tightly controlled within the British and US Pharmacopoeias.

25 Despite these advances in the understanding of clavulanic acid biosynthesis it is still a highly desirable goal in the pharmaceutical industry to continue to improve production methods for clavulanic acid, both for reasons of cost and for reasons of safety.

The following definitions are provided to facilitate understanding of certain terms used frequently herein:

30 "Gene" as used herein also includes any regulatory region required for gene function or expression.

"*cvm*" genes as used herein refers to any of the genes *cvm1*, *cvm2*, *cvm3*, *cvm4*, *cvm5*, *cvm6* or *cvm7* as defined hereinabove.

"*cvmpara*" genes as used herein refers to any of the genes *cvm6para* or *cvm7para* as
35 defined hereinabove.

"*orf*" genes as used herein refers to any of the genes *orf2*, *orf3*, *orf4*, *orf5*, *orf6*, *orf7*, *orf8*, *orf9*, *orf10*, *orf11*, *orf12*, *orf13*, *orf14*, *orf15*, *orf16*, *orf17*, or *orf18* as defined hereinabove.

"*orfpara*" genes as used herein refers to any of the genes *orf2para*, *orf3para*, *orf4para* or *orf6para* as defined hereinabove.

"Disrupted" as used herein means that the activity of the gene (with regard to 5S clavam production) has been reduced or eliminated by, for example, insertional inactivation using an antibiotic resistance gene, preferably apramycin (Paradkar, A.S and Jensen, S.E (1995) *supra*), or other mutagenesis technique (for example those disclosed in Sambrook et al (1989) *supra*). Other mutagenesis techniques include insertion of other DNAs (not antibiotic resistance genes), site-directed mutagenesis to either change one or more bases in the gene sequence or insert one or more bases into the sequence of the gene.

"Deleted" as used herein means that the gene, or a segment thereof, has been deleted (removed) from a larger polynucleotide which, before the deletion was performed, included said gene or segment thereof. When the polynucleotide bearing the deletion is introduced into the genome of the microorganism by means of gene replacement technology (Paradkar and Jensen (1995) *supra*) the activity of the gene or protein encoded thereby is eliminated or reduced such that the levels of 5S clavam produced by the microorganism are reduced. The deletion may be large (for example the complete open reading frame with or without regulatory control regions) or small (for example a single base pair resulting in a frameshift mutation).

"Reduced" as used herein means that the levels of 5S clavam produced by the microorganism of the invention are lower than the levels produced in the corresponding *S. clavuligerus* strain which has not had the relevant open reading frames disrupted or deleted. The corresponding *S. clavuligerus* is therefore the "parent" strain into which the disrupted or deleted open reading frames were subsequently introduced to generate the microorganism of the invention.

"At least maintained" as used herein means that the level of clavulanic acid produced in the microorganism of the invention is the same or greater than that produced in the corresponding *S. clavuligerus* strain which has not had the relevant open reading frames disrupted or deleted. The corresponding *S. clavuligerus* is therefore the "parent" strain into which the disrupted or deleted open reading frames were subsequently introduced to generate the microorganism of the invention.

The present invention concerns new processes for making clavulanic acid using newly identified *S. clavuligerus* genes. Using a probe derived from *orf4* a fragment of the *S. clavuligerus* genome has been isolated and has been shown to comprise a number of genes that when disrupted are shown to affect 5S and 5R clavam biosynthesis in *S. clavuligerus*.

Sequence analysis of the fragment has indicated the presence of a gene showing high similarity to *orf4* (hereinafter called *orf4par*). However surprisingly further sequence analysis of the regions flanking the *orf4par* gene has revealed a new cluster of genes

comprising paralogues of genes previously identified in both the clavulanic acid (*cas2* cluster) and 5S clavam (*cas1* cluster) gene clusters.

Accordingly the invention provides a *S. clavuligerus* microorganism comprising DNA corresponding to one or more open reading frames essential for 5S clavam biosynthesis, wherein said open reading frames are disrupted or deleted such that the production of 5S clavams by said *S. clavuligerus* is reduced and clavulanic acid production is at least maintained, wherein the open reading frames are selected from:

- a) *cvm6para* (SEQ ID NO:1);
- 10 b) *cvm7para* (SEQ ID NO:2);
- c) *cvm6para* and *cvm6* (SEQ ID NO:5); or
- d) *cvm7para* and *cvm7* (SEQ ID NO:6).

In a second aspect the invention provides a *S. clavuligerus* microorganism comprising DNA corresponding to one or more open reading frames essential for 5S clavam biosynthesis, wherein said open reading frames are disrupted or deleted such that the production of 5S clavams by said *S. clavuligerus* is reduced and clavulanic acid production is at least maintained, wherein the open reading frames are selected from:

- a) *cvm6para* and one or more of *cvm1* (SEQ ID NO:7), *cvm2* (SEQ ID NO:8), *cvm3* (SEQ ID NO:9), *cvm4* (SEQ ID NO:10), *cvm5* (SEQ ID NO:11), *cvm6*, *cvm7* or *cvm7para*; or
- 20 b) *cvm7para* and one or more of *cvm1*, *cvm2*, *cvm3*, *cvm4*, *cvm5*, *cvm6*, *cvm7* or *cvm6para*.

The genes *cvm1*, *cvm2*, *cvm3*, *cvm4*, *cvm5* and *cvm6* are disclosed in Mosher et al (1999) *supra* and WO98/33896 (*cvm1* is *orfup1*, *cvm2* is *orfup2*, *cvm3* is *orfup3*, *cvm4* is *ordwn1*, *cvm5* is *orfdown2* and *cvm6* is *orfdown3*). The *cvm7* gene, found to be a further 5S clavam specific gene of the 5S clavam (*cas1*) cluster, has been identified during work leading to the present invention and is disclosed hereinbelow.

In a further aspect the invention provides isolated polynucleotides comprising the *cvm6para* and *cvm7para* open reading frames which are used in the preparation of the *S. clavuligerus* microorganism of the invention. Preferably said polynucleotides comprise open reading frames selected from the group consisting of:

- 30 a) *cvm6para*;
- b) *cvm7para*;
- c) *cvm6para* and *cvm6*;
- d) *cvm7para* and *cvm7*;
- e) *cvm6para* and one or more of *cvm1*, *cvm2*, *cvm3*, *cvm4*, *cvm5*, *cvm6*, *cvm7* or *cvm7para*; or
- 35 f) *cvm7para* and one or more of *cvm1*, *cvm2*, *cvm3*, *cvm4*, *cvm5*, *cvm6*, *cvm7* or *cvm6para*.

In another aspect the present invention provides vectors for cloning and manipulating the *cvm* polynucleotides disclosed herein and which can be used in the preparation of the *S.*

clavuligerus microorganism of the invention. Processes for using these vectors to make the *S. clavuligerus* microorganism of the invention are also provided.

The encoded polypeptides from *cvm6para* and *cvm7para* are also provided by the invention (SEQ ID NO:3 and SEQ ID NO:4 respectively).

5 The invention further provides a polynucleotide comprising one or more open reading frames encoding one or more enzymes involved in clavulanic acid biosynthesis wherein said open reading frames are selected from the group consisting of:

- a) *orf2para* (SEQ ID NO:12),
- b) *orf3para* (SEQ ID NO:13),
- 10 c) *orf4para* (SEQ ID NO:14), and
- d) *orf6para* (SEQ ID NO:15).

In a further aspect the invention provides a polynucleotide comprising one or more open reading frames encoding one or more enzymes involved in clavulanic acid biosynthesis wherein said open reading frames comprise one or more of:

- 15 a) *orf2para*,
- b) *orf3para*,
- c) *orf4para*,
- d) *orf6para*

in combination with one or more genes involved in clavulanic acid biosynthesis selected from
20 *orf2*, *orf3*, *orf4*, *orf5*, *orf6*, *orf7*, *orf8*, *orf9*, *orf10* (Canadian patent application CA2108113 and Jensen, S.E et al (2000) Antimicrob. Agents Chemother 44:720-6) *orf11*, *orf12* (Li, R.N et al (2000) J. Bacteriol 182:4087-95), *orf13*, *orf14*, *orf15*, *orf16*, *orf17*, or *orf18* (patent application PCT/GB02/04989).

Vectors comprising such polynucleotides are also provided by the present invention
25 together with processes for the use of such vectors to prepare strains of *Streptomyces clavuligerus* which can be used to produce elevated levels of clavulanic acid.

Strains of *Streptomyces clavuligerus* so produced and methods for using them to produce clavulanic acid by fermentation are also provided.

Thus the invention further provides a *Streptomyces clavuligerus* microorganism
30 comprising a vector comprising a polynucleotide comprising one or more open reading frames encoding one or more enzymes involved in clavulanic acid biosynthesis wherein said open reading frames are selected from the group consisting of:

- a) *orf2para*,
- b) *orf3para*,
- 35 c) *orf4para*, and
- d) *orf6para*.

In a further aspect the invention provides a *Streptomyces clavuligerus* microorganism comprising a vector comprising a polynucleotide comprising one or more open reading frames encoding one or more enzymes involved in clavulanic acid biosynthesis wherein said open reading frames are selected from the group consisting of:

- 5 a) *orf2para*,
- b) *orf3para*,
- c) *orf4para*,
- d) *orf6para*

in combination with one or more genes involved in clavulanic acid biosynthesis selected from
10 *orf2*, *orf3*, *orf4*, *orf5*, *orf6*, *orf7*, *orf8*, *orf9*, *orf10* (Canadian patent application CA2108113 and Jensen, S.E et al (2000) Antimicrob. Agents Chemother 44:720-6) *orf11*, *orf12* (Li, R.N et al (2000) J. Bacteriol 182:4087-95), *orf13*, *orf14*, *orf15*, *orf16*, *orf17*, or *orf18* (patent application PCT/GB02/04989).

The present invention also contemplates a *S. clavuligerus* micororganism comprising a
15 combination of one or more disrupted or deleted *cvm6para* or *cvm7para* genes, optionally in combination with other disrupted or deleted 5S genes previously disclosed, together with vectors comprising *orf2para*, *orf3para*, *orf4para* or *orf6para* genes, optionally in combination with other clavulanic acid biosynthetic genes (selected from the genes *orf2* to *orf18*) previously disclosed.

Polynucleotides of the invention can be isolated by conventional cloning methods, such as
20 PCR or library screening methods, using the sequences disclosed herein and in Mosher et al (1999) *supra*, WO98/33896, Canadian patent application CA2108113, Jensen, S.E et al (2000) *supra*, Li, R.N et al (2000) *supra* and patent application PCT/GB02/04989, as indicated hereinabove. Examples of such cloning methods are described in, for example, Sambrook, J et al (1989) Molecular cloning, a laboratory manual (2nd Ed) Cold Spring Harbor Laboratory, Cold
25 Spring Harbor, New York.

Polynucleotides comprising individual open reading frames can be isolated and ligated together into vectors in a variety of combinations as defined hereinabove using techniques well know in the art. The choice of vector will depend on the function being carried out, for example cloning, expression, gene inactivation or transfer into *S. clavuligerus* eg. for gene replacement. In
30 all cases a variety of vectors are available to the skilled person and are well known in the art. For example such vectors are known from Sambrook, J et al (1989) *supra* for general cloning vectors Hopwood, D.A et al (1985) *supra* for Streptomyces vectors, Paradkar and Jensen (1995) *supra*, Mosher et al (1999) *supra* and WO98/33896 *supra* for gene disruption and gene replacement vectors and CA2108113 *supra* for vectors suitable for expression of genes in *Streptomyces*
35 *clavuligerus*. However the choice of vector is not limited to just those disclosed in these sources.

Further, in the case of the gene combinations involving the *orf2para*, *orf3para*, *orf4para*, *orf5para* and *orf6para* genes the skilled artisan would be able to design suitable DNA constructs

to ensure that each open reading frame is suitably positioned relative to a transcriptional promoter, whether this be the native promoter or a heterologous promoter that also functions in the *Streptomyces clavuligerus* background, or indeed other regulatory sequence, in such a manner that expression of each open reading frame is optimally achieved.

5 Subsequent manipulation of the polynucleotides, in particular with respect their introduction into the *Streptomyces clavuligerus* background, can be carried out according to standard methods as disclosed in, for example, Hopwood, D.A et al (1985) *supra*. Disruption of gene sequences, and subsequent gene replacement, can be carried out according to the method of Paradkar, A.S and Jensen, S.E (1995) *supra*. Deletion of gene sequences can be carried out using
10 well established techniques, for example that disclosed in WO98/33896.

Microorganisms of the invention can be prepared from *Streptomyces clavuligerus* strains including, but not limited to, *Streptomyces clavuligerus* ATCC 27064 (American Type Culture Collection, Manassas, Virginia, USA), alternatively available as NRRL 3585 (Northern Regional Research Laboratory, Peoria, Illinois, USA). For example mutant strains of *Streptomyces*
15 *clavuligerus* can also be used including those prepared by genetic engineering techniques, or those prepared by strain improvement methods. Examples of such strains include *Streptomyces clavuligerus* strains 56-1A, 56-3A, 57-2B, 57-1C, 60-1A, 60-2A, 60-3A, 61-1A, 61-2A, 61-3A or 61-4A as disclosed in WO98/33896.

Thus in another aspect the invention relates to a process for improving clavulanic acid
20 production in a suitable microorganism comprising isolating a polynucleotide as described hereinabove, manipulating said polynucleotide, introducing the manipulated polynucleotide into a said suitable microorganism, fermenting said suitable microorganism under conditions whereby clavulanic acid is produced, isolating and purifying clavulanic acid so produced. Manipulation of said polynucleotide may be by means of disrupting or deleting gene sequences in the case of
25 *cvmpara* genes, optionally together with *cvm* genes, or by inserting into vectors suitable for expression in the case of *orfpara* genes, optionally together with *orf* genes.

Preferably the suitable microorganism is *Streptomyces clavuligerus*.

Such fermentation, isolation and purification methods are well known in the art, for example the fermentation methods disclosed in UK Patent Specification No. 1,508,977. Methods
30 for using clavulanic acid in the preparation of antibiotic formulations are similarly well known in the art.

Examples

Example 1 - Materials and Methods

35 In the examples all methods are as described in Sambrook, J. et al *supra*, Hopwood, D.A. et al. (1985) *supra* and Kieser, T et al. (2000) Practical *Streptomyces* Genetics, unless

otherwise stated. Transformation methods can also be found in Paradkar, A.S. and Jensen, S.E (1995) *supra*.

1.1 Bacterial strains, media and culture conditions.

5 *Streptomyces clavuligerus* NRRL 3585 was obtained from the Northern Regional Research Laboratory (Peoria, IL). *S. clavuligerus* was maintained on either MYM agar (Stuttard, C. (1982) J. Gen. Microbiol. 128:115-121) or ISP Medium #4 agar plates (Difco, Detroit, MI).

10 Cultures for the isolation of chromosomal DNA were grown on a 2:3 mixture of trypticase soy broth and YEME as described by Alexander et al.(1998) J.Bact. 180:4068-79. Cultures for analysis of the production of clavulanic acid and other clavam metabolites were grown on Soy medium (European Patent 0349 121) unless otherwise stated. All liquid cultures were grown at 26°C on a rotary shaker at 250 rpm.

15 Manipulation of DNA in *Escherichia coli* was done using strain XL-1 Blue (Stratagene, La Jolla, CA). *E. coli* cultures were maintained on LB agar medium and grown in liquid culture in LB medium at 37°C (Sambrook, J et al (1989)*supra*). Plasmid-containing cultures were supplemented with appropriate levels of antibiotic.

1.2 DNA manipulations.

20 Standard DNA manipulations such as plasmid isolation, restriction endonuclease digestion, generation of blunt-ended fragments, ligation, ³²P labelling of DNA probes by nick translation and *E. coli* transformation were carried out as described in Sambrook J et al (1989) *supra*. Plasmid and genomic DNA isolation from *Streptomyces* spp. was conducted as described in Kieser, T et al (2000) *supra*. Construction of a library of *S. clavuligerus* genomic
25 DNA fragments in the cosmid pWE15 was carried out according to the manufacturer's instructions (Stratagene).

30 Southern analysis of *S. clavuligerus* DNA fragments was conducted at high stringency as described by Sambrook, J et al (1989) *supra*. Hybridization membranes were washed twice for 30 min at 2xSSC/0.1% SDS and once for 30 min at 0.1xSSC/0.1% SDS, all at 65°C.

Example 2 - Preparation of the paralogue cluster DNA fragment

2.1 Cloning and nucleotide sequencing of the *orf4* paralogue

35 A strong and a very weak hybridization signal was consistently observed on Southern blots of *Nco*I-digested *S. clavuligerus* chromosomal DNA when probed with the *orf4* gene (CA2108113). The strong signal corresponded to the *orf4* gene, but the identity of the gene that gave rise to the very weak signal was unknown. Therefore it was decided to clone this

gene. To this end, *NcoI* fragments from *S. clavuligerus* DNA of approximately 4-5kb in size were ligated into *NcoI* digested pUC120 (Vieira, J and J Messing (1987) Methods Enzymol. 153, 3-11) and screened using a colony blot hybridisation method and employing the *orf4* gene as a probe. Plasmid DNA was isolated from potential positive clones and confirmed to carry a 4.3 kb *NcoI* fragment. A representative clone, pO4H-4, was chosen for further study. The sequencing of the 4.3 kb *NcoI* fragment was carried out. Analysis of the sequence generated identified three genes, one which had homology to *orf4* and was called *orf4par*. The two other genes present were found to have homology with *orf6* and *cvm6* and were therefore called *orf6par* and *cvm6par*. This result suggested that this region of DNA may contain a cluster of genes with paralogues in either the clavulanic acid biosynthetic gene cluster or the *cvm* clavam biosynthetic gene cluster.

2.2 Sequencing of DNA flanking the 4.3 kb *NcoI* fragment containing *orf4par*

Sequence analysis of DNA flanking the 4.3 kb *NcoI* fragment containing *orf4par* was achieved by identifying 2 cosmid clones containing the *orf4par* gene. The two cosmid clones containing *orf4par*, 14E10 and 6G9, were isolated from a *S. clavuligerus* pWE15 (Promega, Madison, WI) cosmid bank that had been probed with a 0.46Kb *SalI* fragment that is internal to the *orf4par* gene. These cosmids have been partially mapped using a series of digestions and Southern hybridization experiments (In. Nucleic acid techniques in bacterial systematics. Ed. Stackebrandt, E and Goodfellow, M (1991) John Wiley and Sons, p205-248). Digestion of both cosmids with *EcoRI*, *KpnI* and *NruI* suggest that the insert size of 14E10 is approximately 45 kb and 6G9 is approximately 40 kb. These two cosmid inserts have about 20 kb of overlapping DNA and provided DNA for sequence analysis of regions upstream and downstream of the 4.3 kb *NcoI* fragment containing *orf4par*.

DNA sequence information was generated essentially as described in CA2108113. The DYEnamic ET Terminator Cycle Sequencing Kit (Amersham Pharmacia, Baie d'Urfe, Quebec, Canada) was used. Approximately 13.3 kilobases of contiguous DNA sequence was generated. The nucleotide sequence of the *S. clavuligerus* chromosomal DNA generated in these experiments is shown in SEQ ID No:16.

A number of open reading frames were identified which displayed significant homology with the previously described *orf2*, *orf3*, *orf4*, and *orf6* (CA2108113). These genes have been located within the genome in relation to each other, and are found to be nearly in the same organisation as that of the genes within the clavulanic acid cluster. The genes *orf2par*, *orf3par* and *orf4par* are adjacent to each other and in the same orientation as their counterparts *orf2*, *orf3* and *orf4*. However *cas1* is not downstream of *orf4par* as *cas2* is to *orf4* in the clavulanic acid pathway but is instead within the clavam cluster (Mosher et al (1999) *supra*). Another difference between the clavulanic acid cluster and the paralogue

arrangement is that *orf6par* is end-on-end to *orf4par*, and so is not in the same orientation as *orf2par-4par*, whereas *orf6* is in the same orientation as *orfs2-4* in the clavulanic acid cluster. Surprisingly the gene immediately upstream of *orf6par*, was found to be a gene that had a paralogue in the clavam and not the clavulanic acid cluster. This gene was called *cvm6par*, as it is a paralogue of the *cvm6* gene found clustered with *cas1* (Mosher et al (1999) *supra*). The *cvm6* gene encodes an enzyme that is involved in clavam production (*orfdwn3* in WO98/33896).

Located adjacent to *cvm6par* is a new gene called *cvm7par*. This gene shows homology to *cvm7*, a gene that is located upstream of *cvm3* in the clavam cluster (further described hereinbelow). Upstream of *cvm7* is a new open reading frame, believed to encode a sensor kinase. It encodes a polypeptide of 555 amino acids and shows good similarity to sensor kinase domains of two component response regulator genes.

2.3 Functional analysis of the open reading frames

Computer analysis of the DNA sequence shown in SEQ ID No.16 predicts the presence of 7 open reading frames. A description of each gene is shown in Table 1.

Table 1

Orf Designation	Homology (blast P)
<i>orf2par</i>	acetolactate synthase (67% identity to <i>orf2</i> carboxyethyl arginine synthase CEAS)
<i>orf3par</i>	asparagine synthetase (49% identity with <i>orf3</i> β -lactam synthase BLS)
<i>orf4par</i>	amidinohydrolase (71% identity with <i>orf4</i> amidinohydrolase PAH)
<i>orf6par</i>	ornithine acetyltransferase (47% identity with <i>orf6</i> ornithine acetyl transferase OAT)
<i>cvm6par</i>	aminotransferase (66% identity with <i>cvm6</i> acetylornithine aminotransferase)

<i>cvm7par</i>	Transcriptional regulator (33% identity with <i>cvm7</i> homologue)
Sensor Kinase	Sensor Kinase 47% identity with 2 component system from <i>S.coelicolor</i> A3 (2)

To assess the possible roles of these ORFs in the biosynthesis of clavulanic acid and/or clavams produced by *S. clavuligerus*, insertional inactivation mutants were created by gene replacement essentially as described by Paradkar and Jensen (1995) *supra*.

- 5 However, in order to definitively define the phenotype of these disruptions, it was considered important to disrupt *orf3par*, *orf4par*, *orf6par* and *cvm6par* not only in wild type *S. clavuligerus*, but also in strains of *S. clavuligerus* that were already defective in the expression of *orf3*, *orf4*, *orf6*, and *cvm6* respectively. The *orf3*, *4* and *6* mutants were made as described in United States Patent No. 6,332,106 and the *cvm6* mutant made as described in
- 10 WO98/33896.

Example 3 – Analysis *orf 4*, and *orf4par*

3.1 Construction of *orf4* mutants

- Mutants disrupted in *orf4* (*pah*) were made as described in United States Patent No.
- 15 6,332,106.

3.2 Construction of *orf4par* mutants

- pO4H-4 (4.3kb *NcoI* fragment cloned into the *NcoI* site of pUC120 (Vieira and Messing 1987 *supra*) was digested with *KpnI* (one site in the cloned fragment and one site in the
- 20 vector) and religated to reduce the size of the *orf4par*-bearing DNA insert to 1.7kb thereby generating the plasmid p4K-1. The *orf4par* gene within p4K-1 was disrupted by digestion at its centrally located *EcoNI* site and insertion of the apramycin (*apr*) resistance gene cassette from pUC120apr (Trepanier et al. (2002) Microbiology 148: 643-656) after both fragments had been made blunt by treatment with the Klenow fragment of DNA polymerase I. The
- 25 *KpnI/NcoI* insert carrying the disrupted *orf4par* gene was then inserted into the *EcoRI* site of pDA501 after blunting the ends of both insert and vector. pDA501 is a shuttle vector prepared by fusing the *Streptomyces* plasmid pIJ486 (Kieser, T et al (2000) *supra*) to the *E.coli* plasmid pTZ18R (Stratagene) by means of their *EcoRI* and *BamHI* sites. The resulting construct, 6pDAB, was used to transform *S.lividans* TK24, and finally wild-type *S.*
- 30 *clavuligerus* to thiostrepton (thio at 5µg/ml) and apramycin (apr at 20µg/ml) resistance.

Gene replacement mutants were generated as described by Paradkar and Jensen (1995) *supra*.

3.3 Construction of *orf4/orf4par* mutants

5 An approach was undertaken to generate the double mutant by transforming protoplasts of the *orf4par* (*apr*^r) mutant with the *orf4* (*thio*^r) disruption construct (Aidoo *et al.* (1994) Gene. 147:41-6). Protoplast preparations from *orf4par* mutants, were transformed with the *orf4* disruption construct isolated from *S.lividans*. Transformants were selected on thiostrepton at 5µg/ml and hygromycin (*hyg*) at 50µg/ml. Primary transformants were put
10 through two rounds of sporulation under non- selective conditions in order to generate gene replacement mutants as described by Paradkar and Jensen (1995) *supra*.

3.4 Fermentation analysis of *orf4*, *orf4par* and *orf4/orf4par* mutants

To test the effect of disrupting *orf4*, *orf4par* and *orf4/orf4par* on clavulanic acid
15 biosynthesis, spores from each isolate were inoculated into 20ml of seed medium (European patent 0 349 121) and grown for 2 days at 26⁰C with shaking. 1ml of the seed culture was then inoculated into a final stage Soy medium (European Patent 0349 121) and grown at 26⁰C for up to 3 days with shaking. Samples of final stage broth were withdrawn after three days growth and assayed for clavulanic acid productivity by HPLC (Mosher *et al* (1999) *supra*)
20 and/ or using an imidazole derivatised colorimetric assay (Bird, A.E. *et al* (1982) Analyst, 107: 1241-1245 and Foulston, M. and Reading, C. (1982) Antimicrob. Agents Chemother., 22:753-762).

Fermentation analysis of *orf4* disruptant

The *orf4* disruptant was fermented in Soy medium and compared to wild type *S.*
25 *clavuligerus* for production of clavulanic acid. After 72hrs growth, accumulation of clavulanic acid was reduced by 71%.

From these results it can be concluded that *orf4* is required for efficient production of clavulanic acid as elimination of this gene by disruption causes a reduction in clavulanic acid levels.

30 Fermentation analysis of *orf4par* disruptant

Mutant 5pDA defective in the *orf4par* gene was fermented in Soy medium and compared to wild type *S. clavuligerus* for production of clavulanic acid. After 72hrs growth, accumulation of clavulanic acid was reduced by 12%.

From these results it can be concluded that, like *orf4*, *orf4par* contributes to
35 clavulanic acid biosynthesis as elimination of this gene by disruption causes a reduction in clavulanic acid levels.

Fermentation analysis of *orf4/orf4par* disruptants

When mutants A4-A1 and 3A3-A3, defective in both copies of the *orf4* genes were grown in Soy medium production of clavulanic acid could not be detected.

From these results it can be concluded that under the conditions tested, both genes, *orf4* and *orf4par*, contribute to clavulanic acid biosynthesis as the double disruption, results in
5 a mutant unable to make clavulanic acid.

3.5 Southern Analysis

The *orf4*, *orf4par* and *orf4/4par* mutants were further characterised by Southern analysis. The results confirmed that in these mutants the chromosomal copies of the relevant
10 genes had been disrupted as expected.

Example 4 - Analysis of *orf6* and *orf6par*

4.1 Construction of *orf6* mutants

orf6 mutants were made as described in United States Patent No. 6,332,106
15

4.2 Construction of *orf6par* mutants

The *orf6par* gene was disrupted by introduction of a neomycin resistance gene (*neo^r*) into the *RsrII* site, approximately midway through the coding region. In order to achieve this pO4H-4 was digested with *KpnI* to remove *orf4par* and self ligated to give p5K-6. p5K-6 was
20 digested with *RsrII* and the neomycin resistance gene, released from pFDNeo-S (Denis and Brzezinski (1992) Gene 111:115-118.) as a *PstI/EcoRI* fragment, was inserted after both fragments had been made blunt by treatment with the Klenow fragment of DNA polymerase I. The construct pNeo5K-6A was obtained which has the *neo^R* gene in the same orientation as the *orf6par* gene.

25 A shuttle vector called pNeo5K-6Atsr#14 was constructed by inserting pIJ486 as a 6.2 Kb fragment linearised with *BglII*, into the *BamHI* polylinker site of pNeo5K-6A. The shuttle vector was used to transform *S. lividans* TK24 and finally *S. clavuligerus* WT to thiostrepton (5µg/ml) and neomycin (50µg/ml) resistance. Primary transformants were subjected to two rounds of sporulation under non- selective conditions in order to generate
30 gene replacement mutants as described by Paradkar and Jensen (1995) *supra*.

4.3 Construction of *orf6/orf6par* mutants

orf6/orf6par double mutants were generated by transforming protoplasts of the *orf6par* (*neo^r*) mutant with the *orf6(apr^r)* disruption construct (Mosher et al (1999) *supra*). Protoplast
35 preparations from *orf6par* mutants, were transformed with the *orf6* disruption construct isolated from *S.lividans*. Transformants were selected on apramycin (*apr*) at 50µg/ml. Primary

transformants were put through two rounds of sporulation under non- selective conditions in order to generate gene replacement mutants as described by Paradkar and Jensen (1995) *supra*.

5 4.4 Fermentation of *orf6*, *orf6par* and *orf6/orf6par* mutants

To test the effect of disrupting *orf6*, *orf6par* and *orf6/orf6par* on clavulanic acid biosynthesis, spores from each isolate were tested as previously described in section 3.4.

Fermentation Analysis of *orf6* mutants

10 Mutant 6-1A defective in the *orf6* gene was fermented in Soy medium and compared to wild type *S. clavuligerus* for production of clavulanic acid. After 72hrs growth, accumulation of clavulanic acid was reduced by 57%. From these results it can be concluded that *orf6* is required for efficient production of clavulanic acid as elimination of this gene by disruption causes a reduction in clavulanic acid levels.

Fermentation Analysis of *orf6par* mutants

15 Mutant 14-2B(2) defective in the *orf6par* gene was fermented in Soy medium and compared to wild type *S. clavuligerus* for production of clavulanic acid. After 72hrs growth, accumulation of clavulanic acid was reduced by 27%. From these results it can be concluded that, like *orf6*, *orf6par* contributes to clavulanic acid biosynthesis as elimination of this gene by disruption causes a reduction in clavulanic acid levels.

20 Fermentation Analysis of *orf6/orf6par* mutants

Two separate mutants defective in both *orf6* and *orf6par* were fermented in Soy medium and compared to wild type *S. clavuligerus* for production of clavulanic acid. After 72hrs growth, accumulation of clavulanic acid was reduced by an average of 65%.

25 From these results it can be concluded that both *orf6* and *orf6par* are necessary for efficient production of clavulanic acid since disruption of either copy of the gene causes a reduction in clavulanic acid production. Inactivation of both copies of the gene caused a further decrease, but not a complete loss of clavulanic acid producing ability.

4.5 Southern Analysis

30 The *orf6*, *orf6par* and *orf6/orf6par* mutants were further characterised by Southern analysis. The results confirmed that in these mutants the chromosomal copy of the relevant gene had been disrupted as expected.

Example 5 – Analysis of *cvm6* and *cvm6par*

35 5.1 Construction of *cvm6* mutants

Construction of mutants disrupted in *cvm6* has already been described in WO98/33896 (*cvm6* is *orf6*).

5.2 Construction of *cvm6par* mutants

A 1.7 Kb *SaII* fragment containing *cvm6par* was released from pO4H-4 and ligated into pUC118 at the *SaII* site. The resulting plasmid was digested with *EcoNI* to release a 140 bp fragment internal to *cvm6par*. In place of this fragment, the neomycin resistance gene from pFDNeo-S, released as an *EcoRI/PstI* fragment, was ligated into *cvm6par* after both fragments had been made blunt by treatment with the Klenow fragment of DNA polymerase I. The neo^R marker was inserted in the same orientation as *cvm6par*. The neomycin containing *SaII* fragment was released with *EcoRI* and inserted into the shuttle vector pUWL-KS (Weimeier, U.F (1995) Gene 165:149-150.) at the *EcoRI* site. The construct was named pNeoSal1.7U.

The plasmid pNeoSal1.7U was used to transform *S.lividans* TK24, and finally *S.clavuligerus* wild type. The resulting *cvm6par::neo* transformants were selected on MYM medium with 50µg/ml neomycin and 5µg/ml thiostrepton and then subjected to two rounds of sporulation under non- selective conditions to give double cross-over mutants.

5.3 Construction of *cvm6/cvm6par* mutants

The construct pNeoSal1.7U isolated from *S.lividans* TK24 was also used to transform the *cvm6* mutant 56-3A, where the apr^R cassette was inserted into *cvm6* in the same orientation as the gene. Transformants were grown on MYM medium with 50µg/ml neomycin and 5µg/ml thiostrepton. The mutants were put through two rounds of sporulation under non- selective conditions as described above and double cross-over mutants were isolated.

5.4 Fermentation of *cvm6*, *cvm6par* and *cvm6/cvm6par* mutants

To test the effect of disrupting *cvm6*, *cvm6par* and *cvm6/cvm6par* on β-lactam biosynthesis, spores from each isolate were tested as previously described in section 3.4.

Fermentation Analysis of *cvm6* mutants

It was reported in WO98/33896 that mutants 56-1A, 56-3A, 57-1C and 57-2B defective in the *cvm6* gene produced elevated levels of clavulanic acid (125-141% of the control strain) and greatly reduced levels of clavam-2-carboxylate and 2-hydroxymethylclavam when cultured in Soy medium.

These results suggest that the *cvm6* gene is required for efficient production of the 5S clavams. Disruption of *cvm6* not only results in a reduction in clavams but also a simultaneous increase in clavulanic acid.

Fermentation Analysis of *cvm6par* mutants

Mutants 3A1, 3A2, 2A-6, 2B-1 and 2B-2 defective in the *cvm6par* gene were fermented in Soy medium and compared to wild type *S. clavuligerus* for production of β -lactam metabolites. After 72hrs growth, accumulations in clavulanic acid were increased by 6-11%. Production of clavam-2-carboxylate and alanyl clavam was abolished and levels of 2-hydroxymethyl clavam reduced by 50-85%.

These results suggest that like *cvm6* the *cvm6par* gene is required for efficient production of the 5S clavams. Disruption of *cvm6par* not only results in a reduction in clavams but also a simultaneous increase in clavulanic acid.

Fermentation Analysis of *cvm6/cvm6par* double mutants

Mutants A-1, A-2, B-1, B-2, C-1 and C-2 defective in both the *cvm6* and *cvm6par* genes were grown in Soy medium and compared to wild type *S. clavuligerus* for their production of β -lactam metabolites. Production of clavulanic acid was increased by 12-27%, production of alanyl clavam and clavam-2-carboxylate eliminated and levels of 2-hydroxymethyl clavam reduced by 70-83%.

These results indicate that, like the *cvm6* and *cvm6par* single mutants, the *cvm6/cvm6par* double mutants produced elevated levels of clavulanic acid and both genes are required for the efficient production of 5S clavams.

5.5 Southern Analysis

The *cvm6*, *cvm6par* and *cvm6/cvm6par* mutants were further characterised by Southern analysis. The results confirmed that in these mutants the chromosomal copies of the relevant genes had been disrupted as expected.

Example 6 – Analysis of *orf3* and *orf3par*

6.1 Construction of *orf3* mutants

Mutants disrupted in *orf3* were made as described in United States Patent No. 6,332,106.

6.2 Construction of *orf3par* mutants

The plasmid p5.7EcoRI ref (pJOE based hyg) was used as the disruption template for *orf3par*. The insert in this plasmid is approximately 5.7kb and includes part of *cvm6par*, all of *orf6par*, *orf4par*, *orf3par* and part of *orf2par* all carried within the plasmid pJOE829 (Kieser, T et al. (2000); Aidoo et al. (1994) Gene. 147:41-6). The disruption vector was constructed by ligation of a thiostrepton resistance cassette (Aidoo et al. *supra*) into *FseI* digested p5.7EcoRI. A unique *FseI* site is located within the insert 507 bp from the start of *orf3par*.

The correct construct was obtained and used to sequentially transform *S. lividans* TK24 and then *S. clavuligerus* wild type. Primary transformants were selected on thiostrepton (5 μ g/ml)

and hygromycin (25µg/ml). The mutants were put through two rounds of sporulation under non-selective conditions as described above and putative double cross-over mutants were isolated.

5 6.3 Construction of *orf3/orf3par* mutants

 The *orf3par* disruption cassette described in section 6.2 was isolated from *S.lividans* TK24 and used to transform *orf3::apra* mutants. Transformants were selected on MYM medium containing thiostrepton (5µg/ml) and hygromycin (25µg/ml). The mutants were put through two rounds of sporulation without selection and double crossover mutants isolated as previously described.

6.4 Fermentation Analysis of *orf3*, *orf3par* and *orf3/orf3par* mutants

 To test the effect of disrupting *orf3*, *orf3par* and *orf3/orf3par* on clavulanic acid biosynthesis, spores from each isolate were tested as previously described in section 3.4.

15 Fermentation Analysis of *orf3* mutants

 Mutants Ap3-1, Ap3-2 and Ap3-3 were fermented in Soy medium and compared to wild type *S. clavuligerus* for production of clavulanic acid. After 72hrs growth, accumulations in clavulanic acid were reduced by 31-71%.

 From these results it can be concluded that *orf3* is required for efficient production of clavulanic acid as elimination of this gene by disruption causes a reduction in clavulanic acid levels.

Fermentation of *orf3par* mutants

 Mutants 3A-1 and 3A-2 were fermented in Soy medium and compared to wild type *S. clavuligerus* for production of clavulanic acid. After 72hrs growth, accumulations in clavulanic acid were reduced by 9%.

 From these results it can be concluded that *orf3par* is required for efficient production of clavulanic acid as elimination of this gene by disruption causes a reduction in clavulanic acid levels.

Fermentation of *orf3/orf3par* mutants

30 Clavulanic acid biosynthesis was completely abolished when mutants 11-1, 11-2, 2-1 and 2-2 defective in both copies of the *orf3* gene were grown in Soy medium and compared to wild type *S. clavuligerus*.

 These results demonstrate that under the conditions tested, both genes, *orf3* and *orf3par*, contribute to clavulanic acid biosynthesis as the double disruption results in a mutant unable to make any clavulanic acid.

6.5 Southern Analysis

The *orf3*, *orf3par* and *orf3/orf3par* mutants were further characterised by Southern analysis. The results confirmed that in these mutants the chromosomal copies of the relevant genes had been disrupted as expected.

5 **Example 7 - Analysis of *orf2* and *orf2par***

7.1 Construction of *orf2* mutants

Mutants disrupted in *orf2* were originally made as described in United States Patent No. 6,332,106. These original *orf2* mutants were subjected to a second round of gene replacement to remove the apramycin resistance gene and replace it with a simple frameshift mutation. The plasmid construct used to create the original *orf2* mutant consisted of a 2.1 kb *EcoRI/BglII* fragment of *S. clavuligerus* DNA carried on a pUC119/pIJ486 shuttle vector, with the *orf2* gene disrupted by insertion of an apramycin resistance gene cassette into a centrally located *NotI* site (United States Patent No. 6,332,106). The disruption plasmid construct used in the second round of mutation was derived from the original disruption plasmid by digestion with *NotI* to release the apramycin resistance gene cassette, treatment with the Klenow fragment of DNA polymerase I to fill in the overhanging ends, and then re-ligation to circularize the plasmid. The resulting plasmid construct carries the entire *orf2* gene but with a frameshift introduced at the location of the destroyed *NcoI* site. The construct was used to sequentially transform *S. lividans* TK24 and then the original *S. clavuligerus orf2* mutant. Primary transformants were selected on thiostrepton (5µg/ml) and then subjected to two rounds of sporulation under non-selective conditions. Putative double cross-over mutants were identified based on their loss of apramycin resistance .

7.2 Construction of *orf2par* mutants

orf2par mutants were generated using a PCR-based targeting kit known as REDIRECT (trade Mark of Plant Bioscience Limited, Norwich, U.K). The plasmids pIJ790 and pIJ773, and the host strain *E. coli* BW25113 were supplied as part of the kit. For this particular application, a pair of oligonucleotide primers, KTA14: 5'-CCATCCCGGCGCCCGTCCGATGCGAAGGAGATCTCCATGATTCCGG-
GGATCCGTCGACC-3' and
KTA15: 5'-CGGGGCCGGGCATGGTGAAGTCTCGTCCTCCACGGTGGTCATGTAGGC-
TGGAGCTGCTT-3', designed to disrupt the *orf2par* gene by insertion of an apramycin resistance gene, were synthesized. The *orf2par* disruption cassette was generated by PCR using these two primers with the plasmid pIJ773 as template. PCR conditions used were as described in the user instructions except that no dimethylsulfoxide was used. The *orf2par* disruption cassette was then introduced by electrotransformation into *E. coli* BW25113/pIJ790 which had been previously transformed with the *orf2par* bearing cosmid

14E10 (described hereinabove). Cosmid DNA was isolated from transformants after overnight growth at 37°C to promote loss of the pIJ790 plasmid and analyzed to confirm that the *orf2par* gene had been disrupted. *orf2par* disrupted cosmid DNA was then transferred into wild type *S. clavuligerus* by conjugation. Conjugation was carried out as described by Kieser, T et al (2000) *supra* except that AS-1 medium (Baltz, R. H. Genetic recombination by protoplast fusion in *Streptomyces*. Dev. Ind. Microbiol 21 (1980) 43-54) supplemented with apramycin at 50 µg/ml was used for recovery of transconjugants. Apramycin resistant *S. clavuligerus* transconjugants were subjected to one round of sporulation under non-selective conditions in order to generate gene replacement mutants as described by Paradkar and Jensen (1995) *supra*.

7.3 Construction of *orf2/orf2par* mutants

The PCR-based targeting procedure used to generate the *orf2par* mutants (section 7.2) was also used to generate *orf2/orf2par* double mutants. In this case the *orf2par* disrupted cosmid DNA was conjugated into the *orf2* mutants described above (section 7.1) rather than into the wild type strain. Apramycin resistant *S. clavuligerus* transconjugants were subjected to one round of sporulation under non-selective conditions in order to obtain unigenomic mutant spores that had undergone gene replacement as previously described.

7.4 Fermentation analysis of *orf2*, *orf2par* and *orf2/orf2par* mutants

To test the effect of disrupting *orf2*, *orf2par* and *orf2/2par* on clavulanic acid biosynthesis, spores from each isolate were tested as previously described in section 3.4.

Fermentation Analysis of *orf2* mutants

Mutants defective in the *orf2* gene were fermented in Soy medium and compared to wild type *S. clavuligerus* for production of clavulanic acid. After 72hrs growth, accumulations in clavulanic acid were reduced by 95-98% (Jensen *et al.* (2000) *supra*).

From these results it can be concluded that *orf2* is required for efficient production of clavulanic acid as elimination of this gene by disruption causes a severe reduction in clavulanic acid production.

Fermentation analysis of *orf2par* disruptant

Mutants defective in the *orf2par* gene were fermented in Soy medium and compared to wild type *S. clavuligerus* for production of clavulanic acid. After 72hrs growth, accumulation of clavulanic acid was reduced by 10-30%.

From these results it can be concluded that, like *orf2*, *orf2par* contributes to clavulanic acid biosynthesis as elimination of this gene by disruption causes a reduction in clavulanic acid levels.

Fermentation analysis of *orf2/orf2par* disruptants

Mutants defective in both *orf2* and *orf2par* were fermented in Soy medium and compared to wild type *S. clavuligerus* for production of clavulanic acid. After 72hrs growth, no clavulanic acid production could be detected from the strains contain the *orf2* and *orf2par* mutations. These results demonstrate that under the conditions tested, both genes, *orf2* and *orf2par*, contribute to clavulanic acid biosynthesis as the double disruption results in a mutant unable to make clavulanic acid.

5. Southern Analysis

The *orf2*, *orf2par* and *orf2/2par* mutants were further characterised by Southern analysis. The results confirmed that in these mutants the chromosomal copies of the relevant genes had been disrupted as expected.

Example 8 –Analysis of *cvm7* and *cvm7par*

Sequence analysis had identified two additional genes in the paralogue cluster that did not have obvious paralogues in either the clavulanic acid or *cvm* gene clusters. It was of interest to determine if either of these genes was a paralogue to an as yet unidentified *cvm* gene. Therefore the sequence of the *cvm* cluster (WO98/33896) was extended downstream of *cvm3* (*orfup3* in WO98/33896).

8.1 Extension of *cvm* cluster sequence

The cosmid 10D7 (described in WO98/33896) was digested with the restriction endonuclease *SacI*. From this digestion a 6.8 kilobase DNA fragment containing *cas1* and *cvm1* was isolated and cloned into a pUC119 based plasmid. The resultant plasmid pCEC019 was used as a template to generate sequence information which allowed completion of the partial *cvm3* gene reported in WO98/33896. In addition, the sequence information showed the presence of another open reading frame, *cvm7*, which was incomplete in this fragment. In order to complete the *cvm7* gene sequence, the next adjacent *SacI* fragment from cosmid 10D7, a 1.9 kb fragment, was subcloned. Sequence information was obtained from the end of the clone which contained the remainder of the *cvm7* gene, up to the point where the start codon for the *cvm7* gene could be identified. In total, this resulted in the generation of a further approximately 3.9 kb of new DNA sequence which is described in Sequence ID No.17.

8.2 Sequence analysis

The size of *cvm7* and its orientation relative to the rest of the *cvm* cluster is showed diagrammatically in fig2. Sequence homology searches demonstrated that this gene shares homology with transcriptional regulator genes. In addition *cvm7* also shared 33% identity

with one of the two genes identified in the paralogue cluster that did not have any obvious
 paralogues within the known clavulanic acid or clavam biosynthetic genes. Therefore since
cvm6 and *cvm6para* have been shown to be paralogues, from this sequence data it can be
 concluded that *cvm7* and *cvm7para* are paralogues of genes involved in 5S clavam

5 biosynthesis.

Brief description of the figures

Figure 1. Diagram of the paralogue cluster. The orientation of transcription is shown for each
 gene (direction of arrow)

10 Figure 2. Orientation of *cvm7* in relation to published *cvm* cluster (WO98/33896).

Figure 3. Annotated sequence of the paralogue cluster

Brief description of the sequences

SEQ ID NO:1 *cvm6para* open reading frame
 15 SEQ ID NO:2 *cvm7para* open reading fame
 SEQ ID NO:3 *cvm6para* polypeptide
 SEQ ID NO:4 *cvm7para* polypeptide
 SEQ ID NO:5 *cvm6* open reading frame
 SEQ ID NO:6 *cvm7* open reading frame
 20 SEQ ID NO:7 *cvm1* open reading frame
 SEQ ID NO:8 *cvm2* open reading frame
 SEQ ID NO:9 *cvm3* open reading frame
 SEQ ID NO:10 *cvm4* open reading frame
 SEQ ID NO:11 *cvm5* open reading frame
 25 SEQ ID NO:12 *orf2para* open reading frame
 SEQ ID NO:13 *orf3para* open reading frame
 SEQ ID NO:14 *orf4para* open reading frame
 SEQ ID NO:15 *orf6para* open reading frame
 SEQ ID NO:16 paralogue cluster
 30 SEQ ID NO:17 extended *cvm* cluster (underlined sequence denotes new sequence over that
 disclosed in WO98/33896
 SEQ ID NO:18 *orf2para* open reading frame (reverse complement)
 SEQ ID NO:19 *orf3para* open reading frame (reverse complement)
 SEQ ID NO:20 *orf4para* open reading frame (reverse complement)
 35 SEQ ID NO:21 *cvm6* polypeptide
 SEQ ID NO:22 *cvm3* polypeptide
 SEQ ID NO:23 *orf6para* polypeptide

SEQ ID NO:24 orf4para polypeptide

SEQ ID NO:25 orf3para polypeptide

SEQ ID NO:26 orf2para polypeptide

SEO ID NO:1 cvm6para

5
10
15
20

SEO ID NO:2 cym7para

25
30
35
40
45
50

SEQ ID NO:3 cvm6para polypeptide

55

60

SEQ ID NO:4 cvm7para polypeptide

65

AGAGAAPASASGSVSASVSGSGSGSAPASVPTFFPGSVSGSASVAASVAAPVSGHVS GPGSAFGSVALHRPQTLRGEF
 VHGAQGMRTGQVFPTLPFFVGRGDELRLLESATSAFHTSGRVAFFVGEAGSGKTRLLSELSRVPDSVRTVWASCSES
 EDRPDYWPWTTLRLHYAMWPERMHGFPGLRRALAEELLPEVGPPEQPHSPDGGEEENSGNDGAGDGDSTPAHTLT LAP
 ALAPPRSREAREFTLHDAVCQALLRTVREPVVIMLEDMERADAPSLALLRLIVEQLRTVPLLLVVTRTFR LAHDAELRRA
 5 AAVILQSTGARRVLLNALDARATGELAGGMLGKAPDTLLVRALHERSAGNPYFLVQLRLSLRQGLAAAWETEIPDELAGV
 VLQRLSSVPPAVRRVLDICAVVERSCERRVIETVLRHEGIPLENVRTAVRGGLLEEDPDDPGR LRFVHPLVREAVWDDLE
 NTRRPVSRSSALGALATV

SEQ ID NO:5 cvm6

10 GTGCCCCGCTCCGACTCGAAGCACTGGACCGTGCCACCCTCATCCACCCACCCTCTCCGGAAACACCGCGGAACGGAT
 CGTGCTGACCTCGGGGTCCGGCAGCCGGGTCCGCGACACCGACGGCCGGGAGTACCTGGACGCGAGCGCCGTCTCCGGGG
 TGGCCAGGTGGGCCACGGCCGGGCGGAGCTGGCCCGGGTCCGCCCGGAGCAGATGGCCCGGCTGGAGTACTTCCACACC
 TGAGGACAGATCAGCAACGACCGGGCGGTGGAGCTGGCGGACGGCTGGTGGGGCTGAGCCCGGAGCCGTGACCCGCGT
 CTACTTCACCAGCGCGGGCCGAGGGCAACGAGATCGCCCTGCGGATGGCCCGGCTCTACCACCACCGGCGCGGGGAGT
 15 CCGCCCGTACCTGGATACTCTCCGCCGGTCCGCCCTACCACGGCGTCCGATACGGCAGCGGCGGCGTACCCGGCTTCCCC
 GCCTACCACCAGGGCTTCGGCCCCCTCCCTCCCGGACGTGACTTCTGACCCCGCCGAGCCCTACCGCCGGGAGCTGTT
 CGCCGGTTCCGACGTCACCGACTTCTGCTCGCCGAACCTGCGCGAGACCATCGACCGGATCGGCCCGGAGCGGATCGCGG
 CGATGATCGGCGAGCCGATCATGGGCGCGGTCCGCCCGCGGCCCGCGGACTACTGGCCCCGGGTCCGCCGAGCTG
 CTGCACTCTACCGCATCTGCTGATCTCCGACGAGGTGATCACGGGGTACGGGCGACCGGGCACTGGTTCCGCCCGCA
 20 CCACTTCGGCGTGGTCCCGACATCATGGTCACCGCCAAGGGCATTACCTCGGGGTATGTGCCGACGGCGCGGCTCTG
 ACCACCGAGGCGGTCCGCCGACGAGGTCTGCGCGACAGGGCTTCCCGCGGGCTTACCTACAGCGGCCATGCCACGGC
 CTGCGCGGTGGCCCTGGCCAACCTGGACATCATCGAGCGCGAGAATCTGCTCGACAACGCCAGCACCGTCCGCGCCTACC
 TGGGCAACCGCTGGCCGAGCTGAGCGATCTGCCGATCTGCGGAGCTCCGGCAGACCGGCTGATGCTCGGTGTCGAA
 CTGGTCCCGACCGCGGAACCGGGAGCCGCTGCGGGCGCCCGGCTCGCCGAGGCCCTGCGCGAGGGCGGGGACCTCT
 25 GCTGCGCGCAACGGCAACGCCCTCATCGTCAACCCCCCGCTGATCTTACCCAGGAAGACGCCGACGAACCTCGTGCGG
 GCCTGCGCTCCGTACTCGCCCGACAGGCCGGACGGCCGGGTGCTCTGA

SEQ ID NO:6 cvm7

30 ATGAAGTACGACATAACCCACCATCCGGCCTTCGGTTCGACCTCTCCGCCCGTTGACCGTGACCGCCGGCGAGCAACC
 CGTGGACCTGGGCGCGCCACGGCAGCGCGCCCTGCTCGCCCTGCTGCTCATCGATGTCCGCAACGTGGTCCCGCTGCCG
 TCATGACCGCGCTCGATCTGGGGGGCGACCCACCGTCCCGGGTCCGGGGGACGCTCCAGGCTTATGTCTCCGACTGCGG
 AAACCTCTGCACCGCCATGACCGTTCCCTTCGCCTTGTCACCAAGCTCCAGGGGTATCTCTCGAAGTGGATTCCGCGAA
 GGTGGACGCGGTGGTTTTTCGAGACACGTGTAGGGAGTGCCGGGAATTGAGCAGGGCCCGGAACCCGAGGCCACCCGGG
 CCGTGGCCTGGTCCGCCCTGGAGATGTGGAAGGGCACACCATGGGCGAGCTGCATGATTATGAATTTGTGGCGGCGGAG
 35 GCGGACCGGCTGGAAGGAATCCGGTTACGCGCGCTGGAGACCTGGTCCAGGCGTGTCTCGATCTCCAGCACTATGAAGA
 GGTTCGATTTAGCTCGCGGAGGAGATCCACCGCAATCCGGAACCTGGAACGGCTGGGCGGTCTCTTCATGCGGCCGAGT
 ATCATTCCGGACGGTCCGCGGAAGCCCTGTTGACGTATGAACGTATGCGTACCGCGGTGGCGGAGAATCTGGGGCCGAT
 ATCAGTCCGGAGCTCCAGGAACCTCATGGAAGATTCTGCGCCAGGAACCTCACGAGACACCCGCCGCGCATCGACGGC
 CTCCCTCACACGGGCGCGGGCCCGCACGGGCCCCCGCCCTGGCCGAAACCGGCACCCCGCCGACCCGCGGACATGG
 40 CCGAAACACGGTGGCGGAGGAAAGCGCCGCGCCCCCGCCCGGCGGCGCCCGGAGACCCCGCCCGCCATGCCGTCCCC
 GTACCGCTCCCCCATCCGTACGGGGCGTCCCGCGGTACCCCGGTGCTTCCCGGTCCCCCGTCCCGCTCCGCTTCCGTT
 AGCGGCACCCCGAGACCGAGGACCCGCGCGCCCGCCCTCCCTCCCGGGCGGCGGACTCATCGGCCGCC
 GCGCCGAACCTGCGCAGGTGCGGCTGCTGCTGACGAAGACCCGCGCGGGCCACGGCCATGTCTGCTGGTCTGCGGCGAA
 CAGGGCATCGGGAAGACCCGGCTCCTGGAGCACACCGAGCACACCTGGCCGCGGGCGGTTCCGGGTGGTCCGTTTCGCA
 45 CTGCGTCCGCCACCTCCCGGCACCGGGCTACTGGCCCTGGGAGCACCTCGTACGCCAGCTCGACCCGGACAGCGGCCTCG
 GTGACGACGGCGACCGGACCCCGTCCGCCAGGCGGATGGCTGCCGGAACACCACTCACCCACAGATGCGGATCTGC
 CGGACGGTGTCTCGCCGCGCGCGGCGGACCCCGCTCTGTTGATCTTGAGGATCTGCACCTCGCCACCGCGCGGTCTC
 GGATGTGCTCCAGCTCTGGTCAAACAGATCGGCCAGGCCCGCTCATGGTCTGCGCACCCCTGCGCGAGCACGATCTCG
 CCGGGACCCCGCGTCCGCGGGCCGTGGGCCGATCTCCAGCGGGCAACACCGGCACCCCTCCGGTGGACGGGCTC
 50 ACCGAGGAGCAGAGCCGGGAGCTGATCGTCTCGGTGCGGGGGCCCCGTTCCGCGCCCATGACGCCAACGGCTCCAGCG
 CGCCTCGGGCGGCAACCCGTTTCTGCTGCTCAGCATGGTACAGGGGAGGACGGCACCCAGGAGTGGGCACGGCCGTGCG
 TCCCGTTCCGAGGTGCGCAGGTGCTGCACGAGCGGCTGAGCGAATGCTCCCGTCCACCCAGGACGTGCTACGCTCTGC
 GCCGTGCTCGGCATGAGCGTGCGCCGACCGTGTCTCACGACATCATGTCCAGCTCGACATCCCGCACACCGCGCTCGA
 CGACGCGCTCGGCACGGGCTGCTGCGCCACGACCGGAACACCGACGGAATGGTCCACTTCGCCCATGGGCTGACCCGGG
 55 ACTTCCTGCTCGACGACACCCCGCGGTACCCCGCGCCCGTGGCACACCGGGTCCCGCCACCTCGCCCTGCGCTTC
 CAGCAGGGCGACGACACCGCGAGATCCGCCGCCATGTCTGGCCCGGGCCGCTGCTCGGCGCCCGCGGGGGTGGC
 CCCCCTGCTGGCGCTGGCCGACCGGGAGCAGTCCCGCTCTCCACGCGGAGGCGCTGCGCTGGAGAGCGGGTTCG
 CGGTCTGCGCGCTGCCCGGGACACCGCGTGTCCCGCTGCAACTCCAGTTGCGCAAACGGATGATGGCGCTGCAC
 GCGCTGATGGACGGCTATGGATCGGCCCGCTCGAGACGTTCTCTCCAGGTACCCAGTGGGAACACGTCTTCGACAA
 60 CACCCAGCCACCGGGTGTGACGCTCAGGCGCTGAGCGCGTACACAGGGCCGCGATGAGCAGGGCGGCGAGCTGG
 CCGGGTGTGTCACGAGCTGGCCGACACGGCGGCGGACCGGAGGCCCGGTGGCGGCGCTGCTATGTGGACCGGCTACC
 CTGATGTGGGCGGACGGTTCGACGAAGCCCTCGCCGCGCTCCGCCAGGGCACCGAGATCAGGACCGCCCTCTGGCCG
 ACACCGCAGGACCGCGCCCGCACGGCGCGGCGCTCCAGGACCGGCGTATCGACTTCGCGCCTATCTGCGGCTCG
 GCCACTGTCTCAGCGGCGACCGGATTAGACCCAGCGCTACCGACGGAACCTCTCCACCTCACCCAGTCCGAACGGTAC
 65 GACCGGCGGTGGGACCGGGCTTCGCCCGCTATGTGGACGCGCTATCGCCGTACGAGAGTGGATGTCCAGGGGGTGTG
 GCTGGCCGCGCGGGCGGGGCTCGACCTCGCCGCGCGTGCAGCTCCCGTCTGGCAGCGGATGCTCGCCGTCCCCCTCG
 GCTGGGCGGAGGTCCACAGGGGGCGACACAAGGGGCTGGCCGGATGCGGGAGGCGCTGCACGAGGCGGCCCGGCAC

CGGACCCTGCTGCGCCGTACGCTCCACCTCGGCCTGCTCGCCGACGCCCTCCAGTACACGGGCGCCCGGGAACAGGCCCG
GCGACGATGTCTCCGCCGTACGGGAGATCGAGCGCCGCGGCGAGTACTTCTGTCTCCGGCCGAGTGGCCCTGGGCCC
GGCTCCTCCACAGCACGGCACCTCCGCCGCGGCGGAGCACCGGGTCTGCCACGGCAGGCACTGA

5 SEQ ID NO:7 cvm1

ATGTCCCGCTCTCCGCCCGAGTCCCCGGCCGGTTCCGTGTCCGCCCGGGTCCGCGTCCGCCGGTCCGCGCCCTGCGGGA
CCTTCCGGTCACTGCCAGGGGCTCGGCTGCCTGCCGACCACCGACTTCTACGGACGCCCGGACCGCGCCCGGGCGACGG
CCACCATCCGCGCCGCGGTGACGCCCGGGGTCAACCTGTGGACACCGCCGACGTCCAGGGGCTCGGCGCCGGTGAGGAG
CTGCTCGGACGGGCGGTGCGGGGCCGCGGGGACGAGGTCTGATCGCCACCAAGTTCCGCGATGGTGCCTCGTCCGACGG
10 CGCCTCCAGGGCTTGTGCGGCGAGCCGTCTACGTCCGCGCGGCTGCGAACGGTCCCTGCGTCTCGGACCGACC
GCATCGACCTGTACTACCAGCACTGGACGGACCCGGCGGTGCCGATCGAGGAGACCGTGGGTGCGGTGGCCGAGCTGGTG
CGCGAGGGCAAGGTCCGACGGTCTCGGTCTCTCCGAGCCCTCCGCGGCCACGCTGCGCCGGGCGGACCGGGTGCACCCGGT
GACGGCGGTGACAGCGAGTGGAGCCTGTGGTCCGCGGGATCGAGGACGAGGTGGTGCCTGTCCGGGAGCTGGGGA
TCGGGATCGTCTGCTTACGCCCTCTGGGACGGGGTTTTCTCACCGGCACCATCCGCACACCGACGATCTGGGGACGAG
15 GACTTCCGCCGGGGCCAGCCCGGTTACGCGCTCCGGCCCTCGCGCGCAACCGCTCGTTGCTGCACCGGTGCGCCCGGT
CGCGGACGGTCTGGGGCTGACCCTGGCACAGCTCGCGCTCGCCTGGCTGCACCACCGGGGCGAGGACGTCTCCGATCC
CGGGCACCGCAACCCGGCCCATCTCGCGGACAATCTCGCCGCCCTCGATCCGGTGGACGACCGGTCCCTCGCGGAG
GTGACGGCCCGATCTCCACCCGGTGTCCGGGGAGCGGTACACCCGGCATTTGCTCGCCATGATCGGCAACTGA

20 SEQ ID NO:8 cvm2

ATGTCCGTGGCATCGGCCGTATGACGGACGAGCAGCGCAAGGCGGTATCACCGCTACTTCAAGGCGTTGACAAACGG
CGGCGTCCGCGAGCGACGGCACCCCGCGATCGACTACTTCGCCGAGGACGCGGTCTTCTTCTCCCAAGTGGGGTCTGG
CCCGGGGCAAGTCCGAGATCGCCCGGCTCTTCGACGACCTCGGGGGCACCATCCGCTCGATCACCCACCATCTGTGGTCC
GTCAACTGGATTCTGACCGGGACCGAACTCTCGCCGCGGAGGGGACCACCCACGGTGAGCACCGGGACGGGCGGTGGCG
25 GCGGGGTGACCCGAGTGGGCGCGCGGGCGTGGTGCAGGTCTACGAGGTGCGGGACTTCTCGTCCACCGGGCCTTCG
TCTATCTGGACCCCGATTACGCGGGCAAGGACACCGCGCTTACCCGTGGCTGTGA

SEQ ID NO:9 cvm3

GTGACCCGGCTCCGGGCCTTTCCGCGCACACCCACGGGTCCGTGTCCGGGAGTCTGCTGCGCCGGGTGGCGGGCCACTA
30 TCCACCGGGGTGGTCTTGGTCAACCGTCCGGCCGAGGCTCCGGGGCAGCCGCCGCCCGCCATGGTGGTGGGGACGTTCA
CCTCGGTGTGCTCGATCCGGTGTGTTGGGTTTCTCCCGCCAGGTCTGTCGACGACCTGGCCGCGGCTCCGGGCGGCC
GGGCGTTTCTGCGTCAATGTGCTCGGCGCGGATCAGGGCCCGGTCTGCGGAGTTTCGCCGGGGCGATCCGGGGCGCTG
GGAGGTGCGGTACCGGACGACGGCCACCGGCTCCCCCGTCTGCTCGACGCGCTCGCGTGGTTCGACTCGAGGTGGCGG
GGGAGACGGAGGGGCGGACCACTGGTTCGTACCGGGGCGGTGCGCGACCTCGGGGTGATCCGCGAGGGTTCCGCCCTG
35 GTCTTCTGCGGGGCGACTACGGGCACCTGGGCCGGGGGCGCGGCTCGGGCCGGGCGGGGCGGCGGTCCGCCGTCTGCC
GGTCTGA

SEQ ID NO:10 cvm4

GTGGAATGCCGCATATTGAGATCGACGAACTGCCGTTGCTGGACGGGGAGGTCTGCGGGACGCCCGGATCGGTTACGC
40 CATGTACGGCACGCCGAACGCCGACGGGACGAACTGGTGTCTGTCCGTCTTCTCGGCCGGGACCACACCGGGTACG
ACTGGCTGATCGGTGCGGGGCTGCCGCTGGACACCCGGCGGTACTGCGTCTGTCACCGCCGGACTCTTCGCAACGGGGT
TCCAGCTCGCCCGGAACCAACCGTCCGGGTCCCGCTTTCGCGTATCACTCCGACAGACAATGTGCGGCGCAGCACCG
GCTGCTCACCGAGGAGCTGGGGTACGGGAATGGCCCTGGTACGGGCTGGTTCGATGGGCGCGGCCACGCCTACAGT
GGCCGTGTGCTGCTACCGGGATGGTGCGCCGATGCGCCCGATCTGCGGGGCGCGGTGAGCGGGCGCGGAGGCGGCTG
45 CTGCTGTCCGGTCTGGCCGCGGCGCTCAGCGCCGACCGCGGGGAGCGGGGGCGGAAGGCGGCGGGCGGGTGTTCGCCG
GTGGGGACCTCGCGTCTTCTTCTGGGCCCCCGTGCCACCGGGAGCTGGGTTTCGCCACCCGCGAGGAGTACCTACCG
GCTTCTGGGAGCAGGTCTTCTCTCGGGCCCGCGCGCGGATCTGCTCACCATGGTGCACCTGGGAGAACACGGAT
GTGGGGGCGACACCCGGGGCGGGGGGAGCGTCCAGGCGGCGTGGCCTCCGTACGGCGCGGGGCGGTGGTGTGCCGG
CGCCCTGGACGTGTGTTTCGCGCTCGAGGACGAGAAGCGGTGGCCGATCTGCTGCCGTATGCTCGTGGAGGTGATCC
50 CGGGAGTGTGGGGGCATCTCGCGGGGTCCGGGGGTCCGCCGCGGACCGGGAGTTTCATCGGGGGCGCGTGCAGGCGGCT
CTGGACAGCCCGGTGGACGGGGGCTGA

SEQ ID NO:11 cvm5

GTGAAGTCCATTCTCTTCTATCTGCCAACGGTCCGGCAGTCATGCGCAGGTCCAGCGGGGTATGGCGGGGGTCAATCCGCA
55 GAACTACCAGAACATGCTCCGGCAGCTCACCCGGCAGGCGCAGGCGGCCGACGAACCTCGGCTACTGGGAGTGTCTTCA
CCGAGCACCACTTCCACACCGAGGGTTTCGAGGTCTCCAACAACCCGATCATGCTGGGGCTCTACCTCGGCATGCAGACC
CGGCACATCCGGGTCCGCCAGATGGCCAACGTCTGCGCTGCACAATCCGCTGCGGCTGGCCGAGGATCTGGCGATGCT
CGACCACATGACCCGGGGCCGCGCCTTCGTCCGGATCGCGCGCGGGTCCAGAAGCGCTGGGCCGACATCATGGGCGAG
TGTACGGGTGCGGCGGACCCGTGTCGACGCGGGGAGCGGGACCGGCGCAATCGTGCCCTCTTCGAGGAGCACTGGGAG
60 ATCATCAAGAAGGCGTGGACGACCGAGACGTTACCCACTCCGGGGAGCAGTGGACGATCCCGGTGCCGGACCTGGAGTT
CCCCTACGAGGCGGTGCGCGCTACGGCCGGGGCTCGACGAGAACGGCGTCATCCGCGAGGTGGGCATCGCGCCCAAGC
CCTACCAGCGCCCCACCGCCCGTCTTCCAGCGGTTACGTTACGTGAGGACACGTTCCGGTTCTGTGCCCGGGAGGGC
GTGGTGGCGATCTGATGAACACCGACGACAGATCTGCGCCGGTGTGGACATCTACCGGGAGGAGGCGGAGGCGGC
GGGCCACCGCACCTGCGGCGGGGCGAGCGGGTCCGGGTGATGAAGGACGTCCTGGTCTCCCGGGACTCCGGCGAGGCC
65 ACCACTGGGCGTCCCGCGGCGGCGGCTTCATCTCGAGAACTGGTTCGGCCCCATGGGCTTACCGAGGCGCTGCGCGCG
ACCGGCGAGACGGGTCCGATCGGCTCGGACTACAAGACCCTGGTTCGACCGGGGGCTGGAGTGGGTCCGCACCCCGGACGA

CATCAACCGCATGATCGAGAAGCTGGTGGAGCGGCACGATCCGGAGTATCTGCTCCAGTGCCAGTACTCCGGGCTGATCC
CGCAGCATGTCCAGCTGCGCAGCCTGGAGCTGTGGGCCACCGAGATCGCCCCAACTGGCTCTGA

SEQ ID NO:12 orf2para

5 TCAGATGGCCAGGGCGGCGAAACCGCCGACTGGAAGTCGTAGGCCACCGGTACCTCGATCAGGAACGGGCGGCCGAGTC
CGGCGCCCTTGGTGAGGGCGGCGAGCAGCGAGGTGCGGTGCGTGCGGACGGCCTCGCAGCCGTTGGCCTCGGCGAGC
TGGACGAAGTCGACGCTTCCGAAGCCGACGGCGGGGCGTGGGAGCGCTGGTGTCCGAGGTTCTGGTACAGCTCGATCAG
GCCGTTGCGGTGCTTGTGACGACGACCATGACGATCGGCAGGCCAGGCGCACGGCCGTCTCGATGTCGGCGCTGTTGG
10 AGTGAAGCCGCGCTGCGCCGCGATGAGGAAGACGGGCTCGCCGGGCGGGCGATCTGGGCGGCCATGGCGGCGGGCAGT
CCGTAGCCGAAGCTGGAGCAGCCCGCGGAGGTGAGGAATCCGTACGGCTGGTGGACTTGGCGAAGAGCACGCCGTAGTG
GCGGAAGAAGCCGATGTGCTGACGAAGGTGCCGTTGTGAGGACGGAGTTCATGCAGTCGATCACCTGGTGGACCCGCA
TGCCGTCCTCGTACTCGGTGGGGTTCGGCGAGGAATTCGGCGACGCGGGCGCGCAGGGCGCTGAGGTGCTGCCGGGTCTTG
GGGCGAGGCCCGAGGTGCGCTGTCGAGCGCGGTGACGAATTGCGCGACGTTGGTGACGATGTGATGTGCGGCGGGAA
15 CAGCTCCGGGATCGGGTTGACCTCGGGGGCGACCCGACCGTGGTCTTGGCCCGGCCCGCGCTCCACATGGAGGGGCGCA
GGTCTCTCGGCGTAGTCGTAGCCGATCGCCAGGAGGAGGTGCGCGGGGCGGAAGATCTCGTCGAGGGCGGGTGGCCGAGA
ATGCCGTCCATGTAGCCGCTGATGGCGCCGTAGTTGAGCGGGTGGTGTGCGGCGAGGACGCCCTTGGCGGTGTAGGTGGT
GACGACGGGGATGTTTCAGCCGCTCGGCGAGGGCGCGCAGGGCGTTCGACGCCCCGCGCGGATGACGGCGCTACCGACGA
CGAGGAGGGGTTCTCGGCCTCGCGCACAGCTCAGCGGCTCGTCGAGGCGGGCGCGCCAGTCGGCGTCCAGGGCGTGG
GTGGCGGTGGCCCGGACAGGGGGGCGTGGTGGGGTGCCGTTGAGTTCAGTTCGGCGCGCGAGGAGGTGCGCGCGGAGGCTGAT
20 GAAGTGGGACCCAGCGGCTCGATCCGGCTGTTGAGGACGGCGCTGTGACGAGGTTGACGATGTCCTCGCCGCGTTTCGA
GCTGGACGCTGAACCTGGTTCAGCGGGCCATCACGGCGGTGCTGTCCAGGCACTGGTGGGTGACGTTGGGGTAGCAGTCG
TAGGACTCGGACTGCGCGGCCAGCGCGATGACCGAGTTCGGTCCAGGGCGGAGGTGGCGACGCCGCTGGCCAGGTTGGT
CATGCCGGGGCCAGGGTTCGCGAAGCACGCTGGGGGCGGTTGGTGATCCGGGCGAGGACGTCGCCCATCACCCGCGCGG
25 TGAACCTCGTGCCGGGTGAGGACGAAGTCAGTCTTCGACCTCGTCGAAGAGAATGGCGGACGCTCCCGGCCGACGACG
CCGAATACATGGTCGACACCGTACTGGTGAAGACGTTCCAGCATGGCTTTCGCGGTGCTGGTGGCCAT

SEQ ID NO:13 orf3para

TCATACGACCACCCGGCCCTGGAGCCTGAGCCTGCGCACCGCGTCGACGGAGCGCCGACCGTCTCGCCGAAGTCCACGT
CCTCCGGCGGCACCGTGTGATGACCACCGCGTCGTACAGGCGCCGTGCCATGGCGCCCTTGACGGCCGTACCTCGTCCG
30 CGCCGGATCCCTTCGGCGAGGAGCAGTCCGGTCCACGCGCTGGTGGTGCCGGACCCCTCGTGGATGCCAGCTTGGGGCG
GGCCACGGTCTCGGCGGGCAGCAGGCCGAGAGGGCTGCCGCAACACCCACTTGTGCGTGCCCGCGGGCGTTTGAGCC
CGGTTTCGAGGGAGACCAGCGCGTCCAGGACCGCGGTCGTCAGTACGGGTGGGTGGTCCACTTCCCGCGCATGCCCGCG
AGGACGGGGACATCTCGTTGAGGCCGTGGAAGCCCGCCATGTGCGCCGCGATCTCGTCGTGAGGGACAGAGCGAGGC
CGTGCGCCGGTGCATACCGCCGAGCGGATGTGCGCGCCGTACCCGGTGGAGTGCAGGAGCGGCCCGGTGTGAGCCGCC
35 GGTAGAGGGCGACGAGCGGCAGCAGGTACTCCAGGACCGTGGGGTGGTGTCTCCGCGCGGCGACCGCCAGGGCAGT
TCCCTGACGAGTTTCGGCCGAGTGGAGCCGATCTCGTGTGCGCGGTGCCAGGTGGACGGCGACCGAGCGGGCGCGCTC
GAACTCGTCGGACACCTCGGTGCCATCGACACGGACCGTGTCCCGGGTGCCAGGGCCCGCTGTGGCGCGGCACTCCCC
CGGAGTCGATGCCGCCGACAGGACGACGGTGGGGGCGCCCTCCCGCGCGCGACCGGGTGGCGACCGCCGTGGCGAGG
CGTTGCGCGACAGGTCCACCGCTCCGTTGCGCGGGCAGCGCCCGGAGAGCGGGGTGTCCAGGTGCGGACCGCCCT
40 GCGGTTGATGTGCGAGCCGCGACTCCGTGACGAGGAGGCGGTCCCGCGGGGACCCGGCAGACCGCCCGCCCCCG
GCGCGGTGTGGGTGCCGGACAGGCCAGCGGCCCGCGGCTCGTGCGCCAGGGTCTTCGCTCGGTGGCGGCGCTCAGC
CCCGTCAGCTCGGCGCGCAGCCACAGCGGTACCGACACCGGCTGGTGGTGGCGCGACGCTGCGCGGAGGCGGAGGCG
GGTGAGCATGCGCGGAACCGTCCGTTTCAGGAGCGGAAGGCCCGGGGCCAGCGCGCCAGGCGGCCAGCAGAGTT
45 CGGCGTCGCGGAGGGCGGAGAGGCCCGGAGCGCTCCGTCAGCTCGGCGCGGTTGTACAGCTCGCCCGCCAGGAGC
AGCCGGACCTGGCCGTGCGCGACAGGACGGCGGACCGCCAGGGTACGCGCCGTTCCGCTCCAGAGCGGGTACGCGGT
GCCGTCGTGACGGGGACATGGGTCCCGCGGACGGCGAAGCGGGGTGCGCTGCCGGGTTCGGAGTGACCGCGGGGGCGC
GCGGGGGCGGCCCTCGGTGCCGATGCGCACCCGGAATCCGTACACGAGGTGGGGCCGGCAT

SEQ ID NO:14 orf4para

CTACCCCCACCGCTGCCCGGCGAAGTCCACGGCGCTCTCGGCGTCCACCGGTCCACCGGTTCTCGGCGTTCTCGGCGT
CGTCCGCGCGCCCGCCCGGTGGCAGGGGAGAGTCCACCGGTGCGGACGCGGGCGACGTGGTGGCGGGCGTACTGGTAG
AGCAGTTCGGCCCCGATCTCCGCGCCAGCAGGGAGGTGATCCCGACGGGTGTCAGCCGGGGACACCTCGACACGTC
GAAGCCGACGGGCTGAGCTGCCCGACACGTGAGCAGGGTCAGCACCTCGCGGAGGACAGCCCGGGGGCGGGTGG
50 TGCCGCTGCCCGGGCGTACGCGGGGTGACGACGTGATGTCGACGAGAGCTACAGCGGAGGCGCGGACGGTGC
CGGATCTGCTCGGCGATGCCGCGCGGTGAGCGCGGGTGAAGTCGCGCGCGGTGACGATGCTGACGCCGTGCCCGCGCGC
GTAGTCCAGGGAGTGGGCGCGGATTGTGGCCGCGGATGCCGACCTGGACAGGCGCTCCGGGTCCACAGGCCCTCTT
CGATGGCCAGCGGAAGGGGTGCGGTGGTGGTAGGTGCCGCGGTAGACGGGTGGGTGGTGTGCTGTGCGCGTCCAGG
TGCAGGACGGCGACCCGGCCGTGGCGGGCGTGCACGGCGCGAGGGCGGCCAGGGAGAGCGAGTGGTCCCCGCCAGCAT
CAGGAACCGCTCGTTGCGTTCCAGGAGCCGGTCAGGGCGACCGTTCGCGGTGTCATCGCCGATCGAGAAGGGGC
60 TGAGGTGCGATGTGCCCCCGTCGACACGTCGATCCGGTTCGAAGACCCCTGGGCCCGGTGATGCCGACCGCGTGGATC
AGGCTGGACTCGTGCCGATGGCGCGCGGCGGAACCGCGCGCGGGCGGGTAGCTGGTGCCTCCGTCGTACGGGGCGCC
GACGACACACGTCATGGCCGATCGGGTGGGCGCGGTGGCGCAGCCGATGAAGGTGCGCGGTTGGGCGTAGCGCGGGG
AGACGGCGGTGGACAC

SEQ ID NO:15 orf6para

ATGCGTGCTCTTCGCCCAGAGGGTTCGCGGTGCACACGGTCACGCCGGATCAGGGGGTCCACGCGGACCTCGCCGT
CATCGCCTCCGACGTTCCCGCGCGGTGGCGCGGTGTTACCCGTTGCGGTTGCGCGCGCGAGTGTGCTGCTCAGCC

5 GGGACGCGGTGCGCCGACGGGATCGCCCGGGGCGTGGTGGTGTCTGTCGCGCAACGCCAACGCCGGGACGGGCCCCGCGGGG
TACGAGGACGCCCGGAGGTGCGCCATCTGGTGGCCGGGATCGTCTGACTGCGACGAGAGGGATGTGCTGATCGCCTCCAC
GGGACCCGTGCGCGAGCGGTATCCGATGTCCCGTGTCCGGGCCATCTGCGGGCGGTGCGCGGGCCCTTACGGGTGCGCG
ACTTCGACGCGCGCGCGGGCGGCCGTGCTGGGCACCGCGGGCGCCCGTCCACGATCCGGCGGGCGGGTGCAGCGACGCG
10 ACGCTGATCGGTGTCGCCAAGGGCCCGGGTACGGGCCCCGGCGGAGCAGGACGACCGGTGACGCTGGCGTTCTTCTGCAC
GGACGCCAGGTGAGCCCCGTGCTCTCGACGACATCTCCGCCGGGTGCGGACCGCGCCTTCCACGGGCTGGGCTTCG
GCGCCGACGCTCCACCGGGCGACGCGCGCCGTTCGTCGCGGATGCCGACGTGGAGCCGTCCGTCCCGGTGGCCAA
CAGGTCTGGGCGCGCTGGCGCTGGACCTGGTACGGGACGTCTCGGGGACAGCGGTGCGGCGCGCCCTGGTACCGGT
GCGGGTACCGGGGCCACGACACCGAGCAGGCGGGCGCGTGGGCGGGCGGTGGTGCAGCGCGCTGCTGAGGGCCG
15 CCGTGCACGGCCCCGACCCGACTGGGCGCGCGTGGCCCGGTGGCGGGTGGACACGGGGACGAAGCCCCCGGCCGTCT
CCCGGGCGGATCAGATCCGGGTGCGCGCGCGGGAGGTCTTCCCCGCCCCCGCGACCGGGCCCCCGGACGCCGTAC
CGCGTATCCGCACGGCGGCGAGGTGACCGTCCATATCGACCTCGGTGTCCCGGGCCGGGCGCCGCGGCTTACGGTCC
ACGGCTGCGACCTCTGCGGGGTACCGCGCCTCGGCGCCGGCCGGGCGCTGA

15 SEQ ID NO:16 para cluster

CCATGGGAGCAGCATCGCAGTGCCTCCCCGGCCGATGCCGCTAGCTGGTAGTCCCCCTGCCGGGTGCCGACCGCCG
GGGCGGTCCCCGGTGGCGCGGCCGATCTAGTGGTGTGCTCCGACGGTGCTGCTGGGTGAGGGGAGTGTGAGGCGGA
TGGTGGTTCCCGCGCCGGGCGGGCTGTGACGCGCAGTTGGCCCGGAGTGCTCCACCCGGTCGGTGAGGCGGACGAGG
20 CCCGAGCCCCGGCAGGGGGCGGCGCCACCGCGCCGTCTGCGGATGCCGACGTGGAGCCGTCCGTCCCGGTGGCCAC
ATGGACGTGACGACGGTGGACCGGAGTGCTTGGCGCGGTGGTACGGGCTCGGAGACGGCGTAGTACGCGCGGTCT
CGACCGGTTCCGGGTGGCGTTCCCCGGTCTGGATGTGAGCCGACCGGGATGGCGGAGCGCGGGCCAGGGCCTTGAGC
GCCGGGCGGAGTCCGCCCTCGGCGAGTACCGCGGGTGGATGCCCGGGCGACCTCCCGGAGTTCGTGACGCGCGCGGC
CAGCCCGTGGTCACTCGTTCGAGTGCCTGATCAGTCTCGGCGTGCAGCGGCACCGACAGTTGCACGGTGGCGACCC
GACGCGCCAGGAGACGAGCGCTGTGGGGCGCTGTGAGGTGCGGTTGATACGCGCGGGCGGTGTGCGGCGCG
25 GCGACGATCCGGGCCGTGACGCGGTGACGCGGCGCGCTGCTTCCGCGTGGCGATGGCGGTGGCCACCAAGTTCCGTGAA
GCCGGCCAGCGGTCTCGGTGTCCGACGGCATCGGCTTGTGTTTCATGACGCCACGCTGAGCGCGCCCCACAGTTGTC
CGTCGACGTTGATCGGCATGCACACCGTGGCGCGGAATCCCCACTCCTTGGCGACGACGAGGCGGGCCCCGAGGACACG
GCCGCGTAGTCTGTCATCCGCGCGGGGACCGCGACTCGAACACAGGGTGTGCACATTCCGGCCCGCGGGCGGTACCTG
GATACCGGCGGGAATACGCGCGGTCTGGTCCAGGCGGCGACATACAGGGCGGTTCGGTGGGCTCGTAACGGCCGA
30 GGACCGCAAGTCCGGCGAGAGGAGCTGTCGGGCTCGGCGCGGACCGCGCGCAACACCTCCTTCGCGGGTGGCGCCGC
GCGACAGGGTCCGACGCGCGCGAGCGCGCGCTGCTCCTCGGCGGCCCCCGCAGCTCCACACGTGCTTGGGTGTTCGC
GATGGCGGTGGCCACGAGGTGGGTGAAACCGGCCAGCCGTCCTCGGTGTGCGGCGGCGAGCGGTTCGCGGTGAGCGAGA
TCGCCATCATACGCCCCACAGCCGTCCCTCGACGTTGATCGGCACGCCGACGACCGAAGCCGCGCGCCCTGGCG
AAGTCCGCGGGTCCCCCGACGACTCGGCGGCGTCTGATCCGCGCGGGCGCCCCGTCTCGGACACGAGCTCACCAC
35 GTTCCGCGGTTCGGGTCCACCCGGGTCCGCGTGGGGAAGAGCGGGCGGTGCGAGACTTCTGGACACGCGCGGCGCG
TCGCCATGCCGTCCGGATCGAGCCTGATGATTCCGGTCACATCGTTGCCGAGCAGTTCTCCGACTTCGGCGGCGACCGTC
GCGAACATCTGTTCCGGTGGGGTGGCCCTGGCCACAGGGTGCACACCCGTCCGAGTGCCGCCCCGTCTCGACGATCTG
TTCGACGACACGACCGTGGCAGGCCCCCTACCGCGCGATGACGCGCGCATACCGGGTATCACGCGACATCAGCATG
ACGTCCGCGGTGAACGCCGTCAACGTGGCCCGCGGAGTCGGGAACACGCGTCCGGAATCAGCCCCGGAACGGCGGGA
40 CCGTCTTCTCCGTCCGCGCGGGGCACTGCGCGCGCGGAATCCGCCCTGACCTCGGGAGTTTTCGAGTAGTGGAT
CAGCGTTTCGGGTGGTGGGAAGGATGTTGGCGCTGGCGCGGATGCGGAAGCCGATCGTTCCAGTACTTCTGGGAAG
TGCGTTCGCGGAGAGTCCGTCCGCTTCCCCGAGTGGGCGCGACGACGCTGCGGGTCTCCACGGGGGAGAGATCCGCGAA
CCGGCGAAGGAGTGGCGTGTGCGACGTTTCGATCCGAGAAGAGTTGCGCCGCTGTCGGGACCCGCGCGGCAACGTCC
CCACCGCGCTCTGTCATCAGCGCCGTCCGCGCGCTCAGCCACGAGAGAAGATCGGATACGAGTGTACGAGTGCAGCGA
45 TGAGGTTCGTACGACGTCCCCGGCTGCGGGTCCGTACCGTCCATACCGTCTTGGGCTGTCTGGGCGTACGCGCCG
ACGGCGGAACTTGGAGTGGGCCCTCGCGTACGCGGGCGTTTTCGCCCTGCTGCTCATCAACCGGGGAGTGTGGTG
CCGGTTCGACTCGATCGTCTTCCGTATCTGGGCAACTCACCACCGGGCGCGGTACCGCGACGCTCCAGTCTATGTGTC
CCGGTTCGCGAACTCTTGGCCGAGTGTGTCTCCCGACGTTTCGACACCCGAATGCTGCACAGCCGCGGGCTACA
CCCTCGCGCTCGGCACCGAGCACATCGACGCGAACCCTTTTTCGAGAGGCCATCAGGACAGGGCGCGGCTCTCGCGCGAG
50 GAGCAGCACCAGGAGGCGGGGCGGTGCTCTGCCAGGCCCTGCTGAGTGGGGCGGGACACCGTACGAGGAGCTGAGCGC
GTACGACTTCGCGCTCCAGGAGGCAATCGGCTGGAGGACGTCGCGTGGGCGCGGTGGAGACATGGGCGCACTGCTGT
TGCGGCTGGGGCGGGACGAGGAGGTGATGGACGAGCTCAAGCCGAGGTGACGCGCAATCCGCTGCGGGAGCGGCTGATC
GGGCGAGTCTATGACGCGCAGTACCGGCTGGGGTGCCAGGCGGACGCGCTCAGGACGTACGAGGCGACGCGGGGCCCT
GGCCGAGGAGTGGGGACCGATCCGGGCAAGGAGTGGCGGCGGTGACGCGCGGATCCTGCGTACGAGCAACGGTCTGG
55 ACCGCGTCTCCCGCGTCCGCGCGCGGTCCGCGGGGTCGGGCGGGGGCGGTGACGGTGTGCGTCCCGGCAACGCGG
TTCAGGCGGTTGACGCGCGCGGTGGCGGGGCGCGGTCGGGCGGCGATGACGTTGGGCGGGCGGGCGGGCGCGG
CCCCGCTCCGCTCCGGTCCGTTTCCGCGTCCGTTTCCGGCTCCGGCTCCGGCTCCGGCTCCGCTCTGCGTCCGTTT
CCACCTTCTTCCCGGCTCCGTTTCTGGCTCGGCGTCCGTTGCCGCGTCCGTAGCCGCGCCGTTTCCGGCCATGTCTCC
GGGCCCCGGTCCGCTTTCGGGTCCGTGGCGCTCCACCGGCGCGAGACCTCCGGGGCGAGCCGGTCCACGGGGCGCGCA
60 GGGGATGCGCACCGGGCAGGTGTTCCACGCTGCCGCGGTTTCGTGGGCGCGGCGACGAGCTGCGCGGTCTGCTGGAGT
CCGCGAGTCCGCGTTCCACACCTCGGGGCGGGTGGCGCTTCGTTCGGCGAGGCGGGCAGCGGCAAGACCCGCTCTC
TCCGAGTTGGAGCGTCCGTTCCGGACAGTGTGCGCACGCTCTGGGCGTCTGTTTCGAGAGTGAGGACCGGCCGACTA
CTGGCGGTGGACGACCGTGTGCGGCATCTGTACGCGATGTGGCCGGAACGTATGCACGGATTCCCCGGTGGCTGCGGC
GCGCACTCGCGGAACGTCTCCGAGGTGGGCGCGGAGCCACAGGGGCGCACTCCCCGACGGGGCGAGGAGAACAGC
65 GGCAACGGGGACGGTGGGGCGACGGGGACAGCACCCCGCGCACACCTCACGCTCGCGCCCCGTCTCGCGCCCCCGCG
CTCCAGAGAGGCTCGTTTACCCTGCACGACCGCTGTGCCAGGCGCTTCTGCGACGGTCCGCGAACCCGTGGTGTATCA
TGCTGGAGGACATGAGGCGGGCGGCGCCCTCGCTCGCCCTCTGGTGGAGCACTGCGCACCGTCCCGCCCCGCTGCTGCTCGTGGTACCACGCGCACCTTCCGGCTCGCGCACGACCGCGAGCTGCGACGGGCGCGCGCGTATCTCCA

5 GTCCGACGGCGCGCGCCGGTCTGCTGAACGCCCTGGACGCACGGGCCACCGGGGAACCTCGCCGAGGGATGCTGGGCA
 AGGCCCCGGACACCTCTCTGCTACGGGCCCTGCACGAGCGCTCCGCGGGGAACCGTACTTCTCTGCTCCAGCTCTCCGC
 TCGCTCCGGCAGGGGCTCGCCGCCCTGGGAGACGGAGATCCCGACGAGCTGGCCGGGTCGTGCTGCAACGGCTGTC
 GAGCGTGCCGCCCGCGTGCGCCGGTCTGACATCTGCGCGGTCTGAGAGCGAGTTGCGAACGGCGTGTGATCGAGA
 10 CCGTGCTGCGCCATGAGGGAATCCCGTGGAGAAGCTCCGTACGGCGGTCCGCGCGGTCTGCTGGAGGAAGACCCCGAC
 GACCCCGGGCGGCTGAGGTTCTGTCATCCGCTGGTCCGGGAGGCCGTCTGGGACGACCTGGAGAACACCCGTCCGCCCGT
 GTCCCGTTCTCCGCGCTCGGGGCGTGGCCACGGTCTGAGTCCCGGGGCCCGGGTCTCGCGCGCGGGCGCGCTTGC
 GCGCTCCCGACGCCGGGCTTGATCCCCGGGGCAGCCGACGCGCAGCCGGTGCAAGGGGCGTCCGACACTGGGCG
 15 GGCGGCGGCGTGGCCGGTCCGCCCCCCACGGCCACCAGGAGCCCCATGGACACGTACGACGCGGATACGTACC
 CGCGGTCCGGCACCCACCCGAGCCGCTCCCGACGCACCTCCCCACGCGCTCCCGGGACCGTCCCGGCACCCGTTC
 GAGCGCGCCCGGACCCGGGCGCGAGGCCGCTGGTCTGCTCGCGCGGACCGCGCCCATATGTTCCACCCGGTCTCTGCC
 CCGGGCGCGGAGACCGACCGTTCTGGTCTCCGGCGCGGTGACCGTACGGGACACCGAAGGGCGCACCTATCTCG
 ACGCTCTGTCGGTCTCGGACTGACCCAGATCGGCCATGACGTGAGGAGATCGCGCAGGCGCGCCGAGCAGATGCGG
 20 ACACCTCGGTCACTTCCACACCTGGGGCACCATCAGCAACGACAAGGCCATCCGACTGGCGCGCGCTCACCGACCTGGC
 GCCCCAGGGTCTCCAGCGCTTACTTACCAGCGCGCGCGGAGGGCGTGGAGATCGCCCTGCGCATGGCCCCGTACT
 TCCACCACGCGACCGGCGAGCCGAGCGCACCTGGATCTTGTGCGCGCGCACCGCTACCACGGCATCGGCTACGGCAGC
 GGTACGGTGTGGGCTCGCCCGCTACCAGGACGGTTCGGCCCGGTGCTGCCCATGTGCACACCTCACGCCGCCCGA
 CCGGTACACGCCGAGCTGTACGACGGCGAGGACGTACGAGTACTGCCGCGCAACTCGCCGCGACCATCGACGAGA
 TCGGCCCGGGCGGATCGCCGCGATGATCGGGGAGCCGGTTCATGGGCGCGGGCGCGCGCTCGTCCCGCGCGGACTAC
 25 TGGCCGCGCGTCCCGCGCTGCTGCGCTCCACGGCATCTGCTGATCTGGACGAGGTCTCACCGGTTCCGGCCGAC
 GGGGACCTGGTTCGCGGCGGAGCACTTCGGGGTGACCCCGCATCTGCTGGTACCGCGAAGGGCATCACTCCGGGTATG
 TCCCGCAGCGGGGTGCTCTGACCGAGGAGTCCGGGACGCGGTGAACGGGGAGACGGGGTTCGGATCGGCTTACC
 TATACCGTACCCACGCGCTGCGCGTCCGCTCGCAATCTGCACATCATCGAACGGGAAGGGTGTGAGGAACGC
 GGTGAAGGTGGGCGACCACTCGCCGGCGGCTGGCGCGCTGCGCGGGTGCCTGGCGGCTCGCGGCACTTGG
 30 GCATGATGCTCGCCGTGAGCTGGTGTGCGACAAGACGGCCGACCCCGTCCCGGGCGGACCCCTCGGGGTCTGGAC
 GCGCTGCGCGAGGACGCGGGCGTTCATCGTCCGGGCCACGCGCGCTCCCTGGTCTCAATCCGGCGTCTGTGATGGACG
 GGCCACGGCGGACGAGGTGGCGGACGGGTGACTCGGTGCTGCGCGGCTGGCACCCGACGGGCGGATCGGCGCGGCCC
 CCGCGCGGGGTGACGAGACCGGCGGCCACCCGCGGGGGCGCGGGTCCGGCACAGCGGCGACCCGGCGCTTCCC
 CGTTTCCCGCGCTTTTCCGTGCCCGCGCGCTTCCCTGCGGCCCTGCCCTGCCCCGTGCGCGCTCTCTCTCCCTCC
 35 GCTGTGGCGCGTTCCTGTTCCAGCGCGTGTGAGCCGCGGCCAAGCGCCCCGTGCCACGGTGGGAGACCGCGCCCGA
 CGGGGCGCGCGGAGCCGGCAAGCCGAAGGGAAGTCCCGTCCGATGCGTGCCTCTTCCGCCAGAGGGTTCCGCGTGACC
 ACGGTACAGCCGGGATCAGGGGGTCCCACGCGGACCTCGCGTTCATCGCTCCGACGTTCCCGCGCGGTTCGGCGCGGTG
 TTCACCCGTTCCGGTTCGCGCGCGCGAGTGTGCTGCTGACCGGGACGCGGTTCGCGACGGGATCGCCCGGGCGGTGT
 40 GTGCTGTCCGCGAAGCCCAACGCGGGGACGGGCCCGCGGTTACGAGTACGAGGACGCGCGGAGGTCTGGTGGCGG
 GGATCGTGCAGTGCAGCAGAGGGATGTGCTGATCGCCTCCACGGGACCCGTTCGGCGAGCGGTATCCGATGTCCCGTGT
 CGGGCCCATCTGCGGGCGGTGCGCGGGCCCTTACCGGGTGCCGACTTCGACGCGCGCGGCGGCGGCGTGTGGGACCGC
 GGGCGCCCGTCCACGATCCGGCGGGCGCGGTGCGCGACGCGACGCTGATCGGTGTGCGCAAGGGGCCGGGTACGGGCC
 CGGCGGAGCAGGACGACCGGTGACGCTGGCGTCTTCTGACAGGACGCGCCAGGTGAGCCCCGTCTCTCGACGACATC
 45 TTCCGCGGGTCCGGGACCGCGCTTCCACGGGTGGGTTTCGGCGCGACGCTCCACCGGCGACGCGCGCGCTTCT
 CGCCAACGGGTCGCGGGCGGGTGGACCTCGTTCGCTTCGACAGGTCTTGGCGCGCTGGCGGCTGACCTGCTAGGG
 ACGTCTGTCGGGACAGCGGTGCGGCGGCGCCCTGGTACGGTTCGGGTACCGGGGCCACGACACCGAGCAGGCGGG
 CGCGTGGGCGGGCGGTGGTTCGACGCGCGCTCGCTGAGGGCGCGGTGACGCGCCGGCACCCGACTGGGCGCGGTGCG
 CGCGTGGCGGGTGGACACGGGACGAAGGCCCGCGCGGTCTCCCGGGCGGATCACGATCCGGGTTCGGCGGCGGGAGG
 50 TCTTCCCGCCCCCGGACCGGGCCCGCCGACCGCTCACCGGATCCGACAGGCGGAGGTGACCGTCCATATC
 GACCTCGGTGTCGCGGCGCGGCGCGCGCTTACGCTTCCAGGCTGCGACCTCTGCGGGGTCGCGGCTCTCGGCGCCTCGG
 CGCGGCGGGCGCTCTGAACGGGCGTCCCGGGCGGACGGCGACCGCGAGGGCGCGGGAGCGCAGGGAACACGGGAGCG
 GGCGCGGTGGTTCGATCGGCCACGGGCGCGCTCCCGTCTGCTCCGTCGCTGTCGCGGCGCGCCCTACCCCAACCGTGC
 CGCGAAGTCCACGGCGCTCTCGGCGTCCACCGCTCCACCGCTTCTCGGCGTCTCGGCGTCTCGGCGCGCGCCCC
 55 GGTGGCAGGGGAGAGTCCACCGGTGCGGACGCGGGCGAGTGGTGGCGCGGGCTACTGGTAGAGCAGTTCCGGCCCCGAT
 CTCCGCGCCAGCAGGAGGTGATCCCGACGGGTCTGACGCGGGGACACCTCGACACGTGAGCCGACGGGCGGTGA
 GCTGCCCCGACACGTGAGCAGGGTACGACCTCGCGGAGGACGCGCGGGGGCGGCTGTGCGGTGCCCGGGGCG
 TACGCGGGTTCGACGACGTGATGTGACGAGACGTACAGCGGACGGCCGCGACGGTGCCTGGATCTGCTCGGCGAT
 GCCGCGCGGTGAGCGCGGGTGAAGTCCGCGCGGTGACGATGCTGACGCGGTGCCGCGCGCTAGTCCAGGGAGTCCG
 60 GCGCGGATTGTGGCCGCGGATGCCGACCTGGACAGGCGCTCCGGGTCCACAGGCCCTCTTCGATGGCCCCAGCGAAG
 GGGTGCCGTGGTGGTAGGTGCCGCGTAGACGGGTGGTGGTGTGCTGTCGCGTCCAGGTGCGAGGACGGCGACCG
 GCCGTGGCGGGCGTGCACGGCGCGCAGGGCGGCGAGGAGAGGTGGTCCCGCGCCAGCATCAGGAACCGTCTGTCG
 GTTCCAGGAGCCGGTTCAGGGCGACCGTTCGCGGTGTCCATCGCCAGGTCCATCGAGAAGGGGCTGAGGTGATGTGCCCC
 CCGTTCGACACGTGATCCGGTTCGAAGACCCCTGGGCCCCGTGATGCGGACGCGGTGGATCAGGCTGGACTCGTGCCG
 65 GATGGCGCGCGCGCGAACCAGCGCGCGGGCCGGTAGCTGGTGCCTCCGTGCTACGGGGCGCGGACGACACACGTCAT
 GGCCGATCGGTCGGGCGGTGGCGCAGCCGATGAAGTTCGCGGTGGGCGTAGCGCGGGGAGACGGCGGTGGACACC
 TGGCCGTTCCCGCGCACCCGCGCTGCTCCGTTCCGTTCCGACGCGCGGCGCACCCCGTCCCGGCTCCGTTCCGTT
 GCCGACCCCGTTCCCGAACGGGCTCCGTTCCCGCTGGAATCCCGTTCCCGCGCGCGCGGCGCGGTCCGGGCGCGGCG
 TGCCCTCCCTCCGAGACGCTCTGCGGTTCTGCGGCGGTGCGGCTCTGCGGGCGGGTGGCGCGCGCCACGCGCGCT
 GCACCGTCCGCGCGCGCGCGGTGCGGTTGCGCGCGCGGTGCGGTTCTGGCCACCGGTGCGGTTCTGCGCGCTCATACG
 ACCACCGCGCCCTGGAGCCTGAGCCTGCGCACCGCGCTCGACGGAGCGCGCACCGTCTCGCGGAAGTCCACGTCCTCCGG
 CGGACCGTGTGATGACACCGCGTGTACAGCGCGCGTGCATGGCGCCCTTGACGGCGTCACTCTGCGCGCGGACG
 TCCCTTCGGCGAGGAGCAGTCCGGTCCACGCGCTGGTGGTGGCGGACCCCTCGTGGATGCCAGCTTGGGCGGGCCACG
 GTCTCGGCGGGCAGCAGGCGGAGAGGGCTGCCGAACACCCACTTGTGCTGCGCGCGCGCGGCTTTGAGCCCGGGTTC

GAGGGAGACCAGCGCTCCAGGACCGCGCGGTCCCAGTACGGGTGGGTGGTCCACTTCCCGCGCATGCCCGCGAGGACGG
 GGGACATCTCGTTGAGGCCGTGGAAGCCCGCATGTGCCCCGCGATCTCGTCTGAGGGACAGAGCGAGGCCGTGCGC
 CGGTGCATACCGCCGAGCGGGATGTGCGCGCCGTACCCGGTGAGGATGCGGAGCGGCCCGGTGTGAGCCGCCGGTAGAG
 5 GCGCAGCAGCGCGCAGCAGGTACTCCAGGACCGTGGGGTGGTGTATCTCCGCGCGCGCGACCGCCAGGGCAGTTCCCTGA
 CGAGTTTCGGCCGAGTGGAGCCGGATCTCGCTGTGCGCGGTGCCAGGTGGACGGCGACCGAGCGGGCCCGCTCGAACTCG
 TCGGACACCTCGGTGCCATCGACACGGACCGTGTCCCGGGTGCCAGGGCCCGCTGTGGGCGCGCACTCCCCGGAGTC
 GATGCCCGCGGACAGGACGACGGTGGGGGCGCCCTCCCCGCGCGCAGCCGGGTGCGGACCGCGTGGCGAGGCGTTGCG
 CGACCAGGTCCACCGCCTCCCGTTCCGCGGGCAGCGCCCGGGAGAGCGGGGGTGTCCAGGTGCGGACCGCCCTGGCGGTG
 10 ATGTGCGAGCCGCCACTCCGTGCAGCAGGAGGGCGGTCCCGCGGGGACCCGGCAGACGCCCGCGCCCGCGCGCGGT
 GTGGGTGCCGACAGGCCAGCGCGCGGCCCGGCTCGTGCAGGAGTCTTCCGCTCGGTGGCGCGCTCAGCCCCGTCA
 CGTCCGGCGCGCAGCCACAGCGGTACCGAACCGCGTGGTCCGTGGCCGCGACGGTCCGCGCCGTGGAGGCGTCCGTGAGC
 AGTGGCGCGAACCGTCCGTTCAGGAGCCGGAAGGCCCGGGGCCAGCGCCGCGCAGGCGGCCAGCAGAGTTCCGGCGTC
 GCGAGGGCGCGCAGAGGAGCCGCGAGCGCTCCGTGACGTCCGCGCGCGGTGTACAGCTCGCCGCCAGGAGCAGCCGGA
 CCTGGCGCTCGCGCAGCAGGACGGCGCGGCGCCAGGCTCACGGCCGTTCGCTCCAGAGCGGGTACCGGTGCCGTGCG
 15 TGCACGGGGACATGGGTCCCGCGGACGGCGAAGCGGGTGCGCTGCCGGGTTCGGAGTGACCGCGGGGCGCGCCCGGG
 GCGGCCCTCGGTGCCGATGCGCACCCGGAATCCGTACACGAGGTCCGGGCGCGGCATGGTGAATCGTCTCCACGGTGG
 TCAGATGGCCAGGGCGCGGAACCGCCGACTGGAAGTCCGTAGGCCACCGGTACCTCGATCAGGAACGGGCGGGCGAGTC
 CGGCGCCCTTGGTGAGGGCGCGGAGCAGCGAGGTGCGGTCCGTGGCGCGGACGGCCCTCGAGCCGTGGCCTCGGCGAGC
 TGGACGAAGTCGACGCTTCCGAAGCCGACGGCGGGGGCGTGGGAGCGTGGTGTCCGAGGTTTGGTCCGATCGATCAG
 20 GCGGTTGCGGTCTGTTGACGACGACCATGACGATCGGCAGGCCAGGCGCACGGCCGTCTCGATGTCCGCGCTGTTGG
 AGTGGAAGCCCGCTCGCCCGCGATGAGGAAGACGGGCTCGCCGGGCGGGCGATCTGGGCGGCCATGGCGCGGGCAGT
 CCGTAGCCGAAGCTGGAGCAGCCCGCGGAGGTGAGGAATCCGTACGGCTGGTCCGACTTGGCGAAGAGCACGCCGTAGTG
 GCGGAAGAAGCCGATGTGCTGACGAAGGTGCCGTTGTCGAGGACGGAGTTTCATGCACTGATCACCTGGTGGACCCGCA
 TGCCGCTCTCGTACTCGGTGGGTGCGCGAGGAATTCGGCGACGCGGGCGCGAGGGCGCTGAGTCTGTCGGGTCTTG
 25 GGGGCGAGGCCCGAGGTGCGCTCGTGCAGCGCGGTGACGAATTCGGCGACGTTGGTGACGATGTGATGTGCGCGCGGAA
 CAGCTCCGGGATCGGGTTGACCTCGGGGCGACCCGACCGTGGTCTTGGCCCGCCCCGCGTCCACATGGAGGGGCGCA
 GGTCTCGGCGTAGTCTGAGCCGATCGCCAGGAGGAGGTCCGGCGGGCCGAAGATCTCGTGCAGGGCCGGGTGGCCGAGA
 ATGCCGTCCATGTAGCCGCTGATGGCGCCGTAGTTGAGCGGGTGGTCTGCGCGCAGGACGCCCTTGGCGGTGTAGGTGGT
 GACGACGGGGATGTTACGCCGCTCGGCGAGGGCGCGCAGGGCGTGCAGCGCCCGCGCGGATGACGCGCTACCGACGA
 30 CGAGGAGGGGTTCTCGGCCCTCGCGCACAGCTCAGCGGCCCTCGTGCAGGCGGGCGCGCCAGTCCGCGTCCAGGGCGTGG
 GTGGCGGTGGCCCGGACAGGGGGCGTCCGTGGGGGTGCCGTTTCCGCTCGGCGCGGAGGAGTGCACCGGCAGGCTGAT
 GAAGCTGGGACCCACGGGCTCGATCCGGCTGTTGAGGACGGCGCTGTGACGAGGTTGACGATGTCTCGCCGCGTTTCCA
 GCTGGACGCTGAATTTGGTCCAGCGGGCCATCACGGCGGTGCTGTCCAGGCACTGGTGGGTGACGTTGGGGTAGCAGTCG
 TACGACTCGGACTGCGCGGCGCAGCGCATGACCGAGCTGCGGTCCAGGGCGGAGGTGGCGACGCGGTGGCGAGGTTGGT
 35 CATGCCGGGGCCAGGCTCGCGAAGCAGCGCTGAGGGCGGTTGGTGTATCCGGGCGAGGACGTCGCCATCACCCCGCGG
 TGAATCGTGCCGGGTGAGGACGAAGTCGAGTCTTCCGACCTCGTGAAGAGAATGGCGGACGCCCTCCCGGCCGACGACG
 CCGAATACATGGTGCACACCGTACTGGTGAAGACGTTCCAGCATGGCTTTCCGCGTCTGTTGGCCATGGAGATCTCCTT
 CGCATCGGACGGGCGCCGGGATGGCGCCCCGGAACCGCGGCACCGGGCGGTGCGCACCGGGTGGCGCACACCGTGGGTG
 GTGGCGTTGCCACTGTGCGGATCGCCTCTTGGCGGCGGTCCGACGCCCGGCTTGGACAGAATGGGCAAGGCGCGTTCAAG
 40 GCATGGCGTCCATCGTCTCGTGCGCTTTTCGTGAATCCGTCCGGCGCGGAGGTTCCATCCGATTCGCTCCCTTTC
 CGTCCACCGATCCGAGGAGAATCCATGGATGTCTTGGCGCGGTTGGAGCGCAAGCCAGCCTGAATCTTTTCCCATCGA
 GAACCGGCTGTGCGCGCGCGCCAGTGCCGCGTGGCCACCGACCGCTCAACCGTATCCGTACTCCGAGACCCCGGTGG
 CCGTCTACGGCGATGTACGGGGCTGGCCGAGGTGTACGCGTACTGCGAGGACCTGGCCAAGCGCTTCTTCCGGGCGCGC
 CACGCGGGTGTGCACTTCTGTCCGGTCTGCACACCATGCACACCGTGTGACCGCCCTGACCCCGCCCGGGCGGGCGCGT
 45 CCTGTCTCGCGCCGAGGACGGCGCCACTACGCCAGGTGACGATCTGCCGGGGTTCGGCTACGAGGTGAGTTCT
 TACCTTCGACCGCCGACACCTGGAGATCGACT

SEQ ID NO:17 cvm cluster

GGTACCGGCATCCGACCCAGGCCCGGGCGCAGGACCCGGAGGCAGGCACCGGCACACCC
 50 CGGCCGGGCGGCCCGGCTCCCGGCGGTGGTGTCCGGCGACCCGCAATCGGCAGCCGCC
 CAGGCCCCGGACAGGAGCCCGGCTCAAGGCACCGGCCCTGCGCACCCGCTGAGGCGGCAG
 GTTCTTGACAGCGCGCATCCGCCAGTCCGCGCGGGGACAGCCGCCAGGCGCCCGGCCG
 GCACACCCGTGCGAGCGCCCGGCTCCCGGCGGTGGTGTCCCGGAGGCGGCGACCGGCAG
 CCGGACACGGCCCCGCTCGGGGCGCGGCCAGGACAGGCCCTGGGACCCGCTCGGAC
 55 GCCCCGTTCCGACAGCAGGCCCGTGGGAAGCCCGCGGTGAGGCCCGCAGGCAGCCACCGGT
 CGGCGGGCGGATCAGGTGTTGGCGGGGACTCGTCCGGGAAGATCTTTGTGACGACGGTC
 CCGTCTCGGTGAGATAGCCGTGCAGCATCCCGGGGCTGCTGTGCGGCGCGTGAAGTCG
 CCGCGGGGTCGAGGGCGATCACGCCGCCCTGCCCGCGAGCCGGGCGAGGCGCTTGACG
 ATCACCTCGTAAGCGGCGACGCCAGCGCCCTTGAATCTGATCAGATGGGAGAGG
 60 GTCCAGGTCCCGCGCGCCCGGATGAACACCTACCGGCGCGGTTGGCGTCCGCGCGACG
 GTCCGGTTGTGCGCGTAGGTCCCGGCCCGATCAGCGGGAGTCCCGCATCCGGCGCGGG
 AGCTTGTGTTGAGCGCCCGCGGTGGAGGTGGCCGCGCGAGATCGCCGCGCCGCTGAGG
 GCCACCGCGCCACCGTCCCGTCCGACTGCGCGTCCGGCAGTGCCTCCGGGGCCCTCCGG
 GCGGCGGGATCGCCGCTCGTCTCTCGCGCGCAGCAGCGCTCCAGCGGGCCTGG
 65 GTCCAGTAGTAGTCTGGGTGACGCTGCGCAGCCCGTCCCGGGCGCCGAAGTCGTGCGCG
 CCTCGCCGGAGAGGAGGACGTGCTTCGACTTCTCCAGCACCGCGGGCGCCCTCGACC
 GGGTTGCGCAGGAGGTGACCCCGCGCAGCGCTCCCGCTTCAGATCGGAGCCCCGCATC

ACGGAGGCGCTCCAGCTCATGCCCGCGCTCGGCGGTGAAGACGGCGCCCTTGCCCGGTTG
AACAGCGGGTTGTCCTCCAGTTCGCGGACGGCGGCCTCGACCGCGTCCAGGCTGTCCCCG
CCGCGCGGAGCACCCGCTGTCCGCGCGGAGCGCTGCGGCGAGCCCGTCCCAGTACGCC
5 TTCTCCGTTCCGGGCGGTGCTCTCCGGTCCAGGCGGCTCGGCCCGCGGTGGACG
CGATGACCACTGCTACGGGCGTCCGCGCGGGGCTTCCCGCGCGCTCCCCGTTCCCTT
TTCTCCTCCGCGCCTGCTGCTCCTGCTTCTGTTGCGTCTGTGGGCGCGCGGTGGGT
CCATGGCCGCCCCGAGGCCCGGGTACGACGATGAGCGTGGTCTGTCAGCACCGCGCGCG
AGCAGGGAGGACGCCAGCCAGGCGGTGGCGGGGCGGTGGGGCATCGGGCACTCTCTCGGA
CGGGGCTGAGAGCGCTCCGCGCAGTGTACTGACATGCCATGCCCCCTAGTGCCTCC
10 GGAGCCGCTTCCGCGCTCCCCGCGCTCCGCGCGCGCGCGCGCGCGCTCAGTCCAGG
GCCAGGTCTCCGGGGCGGAGCGGGCGAGTCCGGCGAGTGTGCCGAGCGCCCGGGTCA
TCGTCCGCGACGGCGACGCCAGGCCAGCCGACCGCGTGGCGGTGTACGGCCCTGCCCG
GCGCAGAACGCGCGCGCGGGCGTACCCCCGATCCCGTCCGCGCGCGCGCGCGCGAGAG
GTGTCCGCGCGCCAGGCGGGGCGGAGCACCAGCATGTTGTCAGGACGGGGTCCGCC
15 GACACGGCGAAGCCGCTCGAGCGCGCGCGGGCGATCTCTCCGTACGCCCGCTCCGCG
CGCTTGGCGCTACACGCGCGTCCAGCGTGGCGTGGTCTGCCAGCGGACCGCGCGCTCC
AGCGGAACCGCGCGGGGCGGAGACCGCGGAGCGCAGCGCGCGCGCGACCGCTCCGTCC
AGCCCCGGGGGACACCGCGAACCCAGGGTACGCCCGGGGCGAGCCGCTTGGAGAGG
CTGTCCAGGACACCGTCCGCGCGGGGCGACCGCGCGGAGCGAGCGTGCCTCCCG
20 AGGAAGCCCCAGACGGCGTCTCGACCGCGGGAAGTTCAGCCGCTCAGGACCGCGCG
AGCTGGGCGAGACCCCGTCCGACAGGTCGAGGAGAGCGGGTGTGTCAGGGTGGGCTGG
ACATAGACCGCCCGGAGCGGAGCGCTCCGGTGGCCTCGTCCAGCGCTCCGGAATCACC
CCGTCCGCGTCCATGGCGAGGGGACGAGCGTATGCCGAGCGGGCGCGCATCGCCTTG
ACCACGGGGTAGGTCAGCTCCTCGACCCCGAGTCCGGCCCCCGCGCGCACCGCGCGCG
25 AGCACGGCGGAGATGCCTGCCGACCGTTGCCGCGAACAGCACCCGCGGGGTCGCGG
CGCCAGCCGCGCGGCGAGCAGCCGCGCGCGCGCGCTCCGCGCGCTCGGGGTTCCGCGG
GCACCGCGCGCGCGGAGCACGGAATCCAGGACATCGGGCGCGCAGCGCCGCGGAGCCCG
GTGGCCAGCAGCGCGCGCTGCTCGGGGACGACGGGGTGGTTAGCTCCAGGTCTATCCGG
30 CTTCCGCGGGGCTCGGAGAGCGCGGGGCCGACGCCCGCCCGCGCGCGCGGACATAGGTG
CCGCGCCACCTCGCCGACGGTGAAGCTCTGCGGGCGAGTCCCGGTAGACCCGGGCG
CGGTGGAGTCCGCGATGCCGACCCCGCGCGCGCAACTCCCGTTCGCGCGGAAGCGGTCC
CCGGGGCGCAGCCCGCCCGTCTGATCTCCTCGGCGACCGCGTCCGCCACCTGCCGGTAG
TCCTTCATCTCCCGTACCTCCCCTGTCCGGTGGACCGCTTCCGCGCCGGCCCCGCGGACC
35 GTAAACCGGAAGCACCCTGTTCCGGAGCTCGAGTCCCCGTCCGGAAGCTCCCCGTCCGG
AAGCTCCCGTTCCAGAATTGCACCGAGAGCAATATCCCTATTGCAACCGATCAAACAC
CGATCTACGCTCGGAATTGCCTCACACGACCGTTCGAGCATCTGCCGCGACCCGCTACT
GACGCCCCGTCCGAGCCGACCCGCGCGGAGCGCTCGCCCCGCGCGCGCGCTTCGCGCACA
GGAGAGAGAAGGAGATGGTGGAGACCAGCGCACTCGCCGGTGTGGTGATGGTGCCTCG
40 GAATGGTCTCACCPCGGGACCGAACATGATCTATCTCGTCTCCGCGAGCATACCCAGG
GCCGACGTGCGGGGATCATCTCGCTGGGCGGTGTGGCCCTCGGTTTCTGGTCTATCTGC
TCGCGCGAATCTCGGCTGTCCGTGATCTTCTGCGCGTCCGGAAGTGTATGTCGCGG
TCAAATGGCCGGTTCGCGCTATCTGGCATATCTCGCCTGGAACGCCCTGCGGCCGGTG
GCGTGAATGTGTTCTCCCCCGAGGAGGTTCCGCACGACTCCCCGAGCAGGCTGTTACCA
45 TGGGGTGTATGACGAACATCCTCAACCCCAAGATCGCCGTATGTATCTCGCACTCATCC
CGCAGTTCGTTCGACCCGAACCGCGGACCGTGTCTGTTCCAGGGGCTGATTCTCGGCGTC
TCCAGATCGCGGTGAGCGTCCGCGTCAATCTCGGATCTGCGCTGGCGCGGAGCATCG
CCGCTTTCTCGGCGGCCACCCCTTCTGGCTCAGGGTTACGCGCGCGTGTATGGGCGCGG
CGCTCGGTACGCTCGCGGTCTCCCTGGCCCTCGACACCTCCGCCCGCGCGCACCCGTCT
CCTGAGCGCGCGGACCGGGAGCGCGAAGGACCCCTGGGCAACCGTTCGGAGAGC
50 TTATCCGTTACCCCATGAATCCCGATTAAGTGCAATGGCCACTTACCCATGATGGAAC
AGGCCAACCTGACCAAAAAATGAGCCTCCCCACCGGAATAGATGCTTCCAGTGTGAA
GAAATTTATAGCGGAGCGTCTGCCGAACAGGACGCCCATACGCCGCAAGGCGAGAAG
GACATCCGCGCGCGCGGGTCCAGAAAATTCGGAGGACACATCGGACGACCGTCTCCGC
ATCGGCGTCAACTCCGATTACAGAGAATATTGAGTACGTATCAACCGGGCCTTGATCTA
55 CTCAGCTCCATTGTTCTCTCACTCGGGATGTGCAATGAAGTACGACATAACCCACCA
TCCGGCTTCGGTTCGACCTCCTCGGCCGTTGACCGTACCGCGCGGAGCAACCCGTG
GACCTGGGCGCGGACCGGACCGCGCCCTGCTCGCTGCTGCTCATCGATGTCCGCAAC
GTGGTCCCGCTGCGGGTCTATGACCGCGTCTGCTGGGGGCGGACCCACCGTCCCGGGT
CGGGGGACGCTCCAGGCTTATGTGTCCGACTGCGGAACTCCTGCACCGCCATGACCGT
60 TCCCTTCGCTTGTCCACCAGTCCAGGGGATCTCTCCGAAGTGGATTCCGCGCAAGGTG
GACCGCGTGGTTTTCGAGACCGTGTGAGGAGTGGCGGAATTGAGCAGGGCCCGGAAC
CCCGAGGCCACCGGGCGTGGCTGGTCCGCGCTGGAGATGTGAAGGCGACACCATG
GGCGAGCTGCATGATTATGAATTTGTGGCGCGGAGGCGGACCGGCTGGAAGGAATCCGG
TTACGCGCGTGGAGACCTGGTCCAGGCGTGTCTCGATCTCCAGCACTATGAAGAGGTT
65 GCATTTTCAGCTCGGCGAGGAGATCCACCGCAATCCGGAACCTGGAACGGCTGGGCGGTCT
TTCATCGGCGCCAGTATCATTCGGACGCTCGGCGGAAGCCCTGTTGACGTATGAACGT
ATGCGTACCGCGGTGGCGGGAATCTGGGGCCGATATCAGTCCGAGCTCCAGGAACCT
CATGGAAGATTTCTGCGCCAGGAACCTACGGAGACACCGCGCGCGATCGACGCGCTC

CTCACACGGGCGGCGGGCCCGCACGGGCCCCGCCCTGGCCGAAACCGGCACCCCGCC
 GCACCCGCGGACATGGCCGAAACACGGTGGCGGAGGAAAGCGCCGCGCCCCCGCCCCG
 GCGGCGCCCGGACCCCGCCCCCATGCCGTCCCCGTACCGCTCCCCCATCCGTACGGG
 5 GCGGTCCCGCCGGTACCCCGGTGCCTCCCCCGTCCCCCGCTCGGCCCTCCGTTCAGCG
 GCACCCGCGGAGACCGAGGACCCGGAACCGGCGCCGCCCTCCCCCTCCGCCGGGCGGC
 CGACTCATCGGCCCGCGCCGGAATGCGCAGGCTGCGGCTGCTGCTGACGAAGACCCGC
 GCGGGCCACGGCATGTCTGCTGCTGCTGCGGCGAACAGGGCATCGGGAAGACCCGGCTC
 CTGGAGCACACCGAGCACACCTGGCCGCGGGCGCGTTCCGGGTGGTCCGTTCGCACTGC
 10 GTCGCCACCTCCCGGCACCGGGCTACTGGCCCTGGGAGCACCTCGTAGCCAGCTCGAC
 CCGGACAGCGGCCTCGGTGACGACGGCGACGCCGACCCCGTCCGCCAGCGCGAGTGGCTG
 CCGAACACACCTTACCTACACAGATGCGGATCTGCCGACGGTGTCTGCCGCGGGCGCG
 CGGACCCCGTCTCTTGATCTTGAGGATCTGCACCTCGCCACGCGCGGCTCTGGAT
 GTGCTCCAGCTCCTGGTCAAACAGATCGGCCAGGCCCGCTCATGGTCTGCGCACCCCTG
 CGGAGACAGATCTCGCCGGGACCCCGCGTCCGCCGGGCGGTGGGCCGCATCTCCAG
 15 GCGGGCAACACCGGCACCCCTCCGGTGGACGGGCTACCGAGGAGCAGACCGGGAGCTG
 ATCGTCTCGGTGCGGGGGGCCCGTTCCGCGCCCATGACGCCAACGGCTCCAGCGCGCC
 TCGGGCGGCAACCCGTTTCTGTGCTCAGCATGGTACAGGGGAGGACGGCACCCAGGAG
 TGGGCACGGCGTGCCTCCCGTTCCGAGGTGCGCGAGGTGCTGCACGAGCGGCTGAGCGAA
 TGCTCCCCGTCCACCCAGGACGTGCTCAGCTCTGCGCCGTGCTCGGCATGAGCGTGCGC
 20 CGACCGCTGCTACCGACATCATGTCCACGCTCGACATCCCGCACACCGCGCTCGACGAC
 GCGCTCGGCACGGGCTGCTGCGCCACGACCGGAACACCGACGGAATGGTCCACTTCGCC
 CATGGGCTGACCCGGGACTTCTGTCTGACGACACCCCGCGGTACCCGCGCCCGCTGG
 CACCACCGGTGCGCCGACCCCTCGCCCTGCGCTTCCAGCAGGGCGACGACACGCGGAG
 ATCCGCGGCCACTGTCTGGCCGCGGCCCGTCTGCTCGGCGCCCGCGGGGGTGCGCCCC
 25 CTGCTGGCGTGGCCGACCGGGAGCAGTCCCGCTTCTCCACGCGGAGGCGCTGCGCTGG
 CTGGAGAGCGCGTTCGCGGTGCTGCGCGCGCTGCCCGGGACCGCGGTGTCGCGCGTC
 GAACTCCAGTTGCGCAAACGGATGATGGCGCTGCACGCGCTGATGGACGGCTATGGATCG
 GCGCGCTCGAGACGTTCTCTCCAGGTACCCAGTGGGAACACGTCTTCGACAACACC
 CAGCCACCGGGTGTCTGCACGTCCAGGCGCTGAGCGCGCTACCCACGGGCGCCATGAG
 30 CAGGCGGCGGAGTGGCCGGGTGCTGCACGAGTGGCCGACACGGCGGCGGACCGGAG
 GCCCGGTTCGGCGGCTGCTATGTGGACGGCGTACCCCTGTATGTGGGCGGACGGGTTCGAC
 GAAGCCCTCGCCGCGCTCGCCAGGGCACCGAGATCACGGACGCCCTCTGGCCGGACAC
 CGCAGGACCGCCGCCCGCACGGCGGGGACCTCCAGGACCGGCGTATCGACTTCGC
 GCTATCTGGCGCTCGGCCACTGTCTCAGCGGCGACCGGATTCAGACCCAGCGCTACCGG
 35 ACGGAACCTCTCCACCTACCCAGTCCGGAACGGTACGACCGGCCGTGGGACCGGGCCTTC
 GCCCGCTATGTGGACGCGCTCATCGCCGTACCGAGTGCATGTCCAGGGGTGTGGCTG
 GCCGCGCGGGCGGGGCTCGACCTCGCCGCCCGCTGCCAGTCCCGTTCTGGCAGCGGATG
 CTCGCGCTCCCCCTCGGCTGGGCCGAGGTCCACCAGGGGGCGCACGACAAGGGGTGGCC
 CGGATGCGGGAGGCGTGCACGAGGCGGCGCCGCGACCGGACCTGCTGCGCGGTACGCTC
 40 CACCTCGGCTGCTCGCCGACGCCCTCCAGTACACGGGCGCCCGGGAACAGGCCCGGCGC
 ACGATGTCTCCGCGTACGGGAGATCGAGCGCGCGGCGAGTACTTCTGTCTCCGGCCG
 CAGTGGCCCTGGGCGCGGCTCCTCCACAGCCACGGCACCTCCGCCGCGGCGGAGACCGG
 GTCGTCCACGGCAGGCACTGACCCGGGGCGGCCGAGCCGGGCCCGTACGGTACGGGTG
 45 CGGTTCGGGAGGCGTGCACGAGGCGGCGGGCGGGGCGGCCGACGGTTCGGGGGCG
 CGGCGGTGTGGGAGGGGGCGGCCCGGATCGCTCAGACCGGGCAGACGGCGGACCGCG
 CCGCGCCCGGCCGAGCCGCGCCCGGCCAGTGGCCGTAGTCCGCCCGCAGGAAGAC
 CAGGGGCGAACCCTCGCGGATACCCCGAGGTGCGCGACCGCCCGGTGACGAACAGTG
 GTCGCCCGCCTCCGTCTCCCCGCCACCTCGCAGTCCAACACGCGAGCGCGTTCGAGCAG
 50 GACGGGGAGCCGGTGGCCGTGCTCCGTTACGGCACCTCCAGCGCCCGGATCGCCCC
 GGCGAAACTCCGGCAGACCGGGCCCTGATCCGCGCGAGCACATTGACGAGAAACGCCC
 GGCGCCCGGAGCCGCGGCCAGGTGCTCGACGACCTGGCCGGGAGGAAACCCACCAGCAC
 CGGATCGAGCGACACCGAGGTGAACGTCCCCACCACCATGGCGGGCGGCGGTGCCCGG
 AGCCTCGGCCGGACCGGTGACCAGGACACCCCGGTGGGATAGTGGCCCGCACCCGGCG
 55 CAGCAGACTCCCGGACACGGACCCGTGGGTGTGCGCGGAAGGCCCGGAGCCGGGTAC
 AGCCACGGGTAACGCGCGGTGTCTTGGCCGCGTAATCGGGGTCCAGATAGACGAAGGCC
 CGGTGGACGAGGAAGTCCCGCACCTCGTAGACCGTGCACAGCGCCCGGCGGCCACTCG
 GGGTACCCGCGCCGACGCGCCGTCCCGGTGCTACCGTGGGTGGTGGCCTCCGCGGCG
 AGGAGTTCGGTCCCGGTGAGAATCCAGTTGACGGACACAGATGGTGGGTGATCGAGCGG
 60 ATGGTCCCCCGAGGTGCTGAAGAGCCGGGCGATCTCGGACTTGGCCCGGGCCAGACCC
 CACTTGGGGAAGAAGACCGCGTCTCGGCGAAGTAGTCGATCGCGGGGTGCCGTGCG
 CTGCCGACGCGCGGTTGTGGAACGCTTGAAGTACGCGGTGATGACCGCCTTGGCGTGC
 TCGTCCGTATACCGGCCGATGCCACGGACATGAAACGACCTCCAGAGATTCCGGGTGGC
 TGTGCTGGGCTGCGGAAGGGGTGTCGCCCGCGAAGGACGGCGGACGCCGCGGACGCCG
 65 GCGCTCTCCCCGGGACGGGTCCAGCGTCTTGAGAGGGGCTTGGCGGCGGCTTGACG
 CCGTGTGTCGCGCGGTGCGGAACGCGAAGTACCGCCAGCGTACGGGCGTTGCACCG
 GACGTGTACCGCGGTGGGACCCCTCGTACCCCGGAGCCGCGGACCCCGGCGGCTCCG
 GGGGTACGAGCGCGCGGACCGGCCGAGCGAGCCGAGCGGTCGACGGTGCCTGGT
 TCCGGTGTGTCGACAGCTCGGACGGACCGGACGGTGCCTGGTTCGGTGTGTCGGAC

AGCTCGGACGGGTGCGACGGTGCGCGTGGTTCCGGCACGCCGGACGGGTGAGTTGCCGAT
 CATGGCGAGCAATGCCGGGTGTACCGCTCCCCGACACCGGGTGGGAGATCGCGGCCGT
 CACCTCCGCGAGGGACCGGTGTCAGCCGGATCGAGGCGGCGGCGAGATTGTCCGCGAG
 5 ATGGGCCGGGTTCGCGGTGCCGGGATCGGGACGACGTCTCGCCCCGGTGGTGCAGCCA
 GGCGAGCGCGAGCTGTGCCAGGGTCAGCCCCAGACCGTCCGCGACCGGGCGCAGCCGGTG
 CAGCAACGAGCGGTTGCGCGCGAGGGCCGGAGCGCTGAACCGGGGTGGCCCCGGCGGAA
 GTCTCTCGTCCCCAGATCGTGGTGGTGGGATGGTGCCGGTGAGAAAACCCCGTCCAG
 AGGGGCGTAAAGCGACGATCCCGATCCCCAGCTCCCGCGACACGGGACACCTCGTCCTC
 10 GATCCCGCGCGACACAGGCTCCACTCGCTCTGCACCGCGTCACCGGGTGACCGCGTC
 CGCCCCGCGCAGCGTGGCCGCGAGGGCTCGGAGAGACCGAGCCTGCGGACCTTGCCCTC
 GCGCACAGCTCGGCCACCGCACCCACGGTCTCCTCGATCGGCACCGCGGGTCCGTCCA
 GTGCTGGTAGTACAGGTGCGTGGTGGTGCCGAGACGACGAGGGACCGTTGCGAGGC
 CGCGCGGACGTAGGACGGCTCGCCGACAAAGCCCTGGGAGCGCCGTGCGACGAGCGCAC
 15 CATGCCGAACCTTGGTGGCGATCAGCACCTCGTCCCGCGGCGCCGCGACCGCCCGTCCGAG
 CAGCTCCTCACGGCGCGGAGCCCTGGACGTGCGCGGTGTCCAGCAGGGTGACCCCGGC
 GTCGACGGCGCGCGGATGGTGGCCGTGCGCCGGGCGCGGTCCGGGCGTCCGTAGAAGTC
 GGTGGTGGCAGGACCGGAGCCCTGGGCACTGACCGGAAGTCCCGCAGGGCGCGGAC
 CGCGGACGCGGAACCGCGCGGACACGGAACCGGCCGGGACTCGGGCGGAGAGCGGGA
 20 CATAAGGAACCTCCACAGGCGGAGCCGGGAACGGGACGAGGGCGAGGACGGGACGGAACG
 AAGGAGAGGACGGGACGACAGCAGGACGGGACGAGGACGGAACGAGTCCGGGAACCGGGG
 GGGGTGACCGGAACCGGGCCGTCTTGGCCCTCCCCGTCCTCCCCGCCATCCGCGGTTT
 TCCCCGTTCCTCTCCCGTCTCCAGCCAACACCGCCGCCCTTTCCAAGCGCTTGACAC
 GGCACCGACAGCCGCGCGGGCGCCGATGGGGACCGTGCCCGCCGGTGAGCGGCGGT
 GAGCGCCGGTACCGGACCCACGCGCCGCGCCCGGGCGCCCGCAGGGCCCGCGCGGCC
 25 ACCCGGCGCCCGCCCGGCGGAGCGGCGATCCGGGCGGCTCGCTGCAAGAGGAACATCCA
 CAGCCGCACAAGGAGCGCTCCGCACAGTGGGCACACGTCCGCCCCGTCCCCACACCGT
 GGCCGGTCCCCACCGGACAGCACAGCACCGCACAGCACCATCGCACGGCACAGCACAG
 CACCACCGGCACGAGGAACCAAGGAAGGAACCAACACCATGACCTCAGTGGACTGCA
 CCGCAGTACGGCCCGAGCTGCGCGCGCTCGCCCGCCGGGTGCCCCGAGCCCCCGGGCCG
 30 ACCTGTACGCCCTTCTGGACGCGCGCACACAGCCGCGCCTCGCTCCCCGCGGCCCTCG
 CCACCGCGCTGGACACCTTCAACGCCGAGGGCAGCGAGGACGGCCATCTGCTGCTGCGCG
 GCCTCCCGGTGGAGCCGACGCCGACCTCCCCACACCCCGAGCAGCACCCCGGCGCCCG
 AGGACCGCTCCCTGCTGACCATGGAGGCCATGCTCGGACTGGTGGGCGCGCGGCTCGGTC
 TGCACACGGGGTACCGGGAGCTGCGCTCGGGCACGGTCTACCACGAGTGTACCCGTGCG
 35 CCGGCGCGCACCACTGTCTCGGAGACCTCCGAGACGCTGCTGGAGTTCCACACGGAGA
 TGGCCTACCACCGGCTCCAGCCGAACCTACGTATGCTGGCCTGCTCCCGGGCCGACCAG
 AGCGCACGGCGGCCACACTCGTTCGCTCGGTCCGCAAGGCGCTGCCCTGCTGGACGAGA
 GGACCCGGGCGCGGCTCTCGACCGGAGGATGCCCTGCTGCGTGGATGTGGCCTTCCGCG
 40 GCGGGTGGACACCGGGCGCCATCGCCAGGTCAAACCGCTCTACGGGGACGCGGACG
 ATCCCTTCTCGGGTACGACCGCGAGCTGCTGGCGCGGAGGACCCCGGACAAAGGAGG
 CCGTCCGCGCCCTGTCCAAGGCGCTCGACGAGGTACGAGGCGGTTGATCTGGAGCCCCG
 GCGATCTGCTGATCTCGACAACCTCCGACCAACGACGCGCGGACGCCGTTCTCGCCCC
 GCTGGGACGGGAAGGACCGCTGGTGCACCGCTCTACATCCGCACCGACCGCAATGGAC
 45 AGCTCTCCGCGCGGAGCGCGCGGGCGACGTGCTCGCCTTACACCGCGCGGCTGAGCTC
 CCGGTCGACACCGCGCGGCTGAACCCAGGTCCGGGGCCACGGTCCGGCACCGCGCG
 GCTGAGCCCCGGGTCCGGCAGCGGGCGGCTGAACCCCGCCCGGGCCACCGCCCGACC
 GCCCCGCGCACCGGACGCGCCCGCTGTACGGCGGTCCCGCCGGGGCCCGTACACCTGA
 AGCGCCCGGCGGACCGCGCCCGCGCGGGGACGACAGAGCCGGGTGCGGGAGGACGTC
 50 CTCCCGCACCCGGCTCCACCGTTCCGCACCGACCGCACCCGACCGTGCCGACAGGCGCA
 CCGGCACCGCACCGCCCGCGCGCGGACGCAACACAGGCGCCACGCGCCCGCACGGTGCC
 CGCGCTGCTCAGCCCCGTCCACCGGGCTGTCCAGCAGCCGCGCAGCGCGCCCCGATG
 AACTCCCGGTGCGGCGCCGACCCCCCGGACCCCGCAGATGCCCCACACTCCCGGGATC
 ACCTCCAGCGAGGCATACGGCAGCAGATCGGCCACCCGTTCTCGTCTCGACGGCGAAA
 55 CACACGTCCAGGGCGCCCGGACACACGGCCCGCGCGGTGACGGAGGCCAGCGCCGCC
 TCGACGCTCCCCCGGCCCGGGTGTGCCCCCACATCCGTGTTCTCCAGGTGCGCACC
 ATGGTGAGCAGATCCGCGCGCGCGGGCCCGGAGAGGAAGACCTGCTCCAGAGCCGGTG
 AGGTACTCTCGCGGTGGCGAAACCCAGTCCCGGTGGGCACGGCGGGCCAGAAAGGAA
 CGCGAGGTCCCCACCCGCGGAACACCGGCCCGCGCGCTTCCGCCCCGCTCCCGGGCG
 60 TCGGCGCTGAGCGCGCGGCCAGACCGGACAGCAGGACAGGCTGTGCGGGTGTCTACC
 GCGCCCCCGAGATCGGGGCGATCCGGCGACCATCCCGGATGCGACACGGCCACTGG
 TAGGCGTGGGCGCGCCATCGACAGCCCGTGACAGGGCCAGTTCCCGTACCCCCAGC
 TCCTCGGTGAGCAGCCGGTGTGCGCCGCGACATTGTCTGCGGAGTGATCAGCGGAAAG
 CGGGACCCCGACGGGTGGTGGCGGGCGAGCTGGAGACCCCGTTGCCGAAGAGTCCGGCG
 65 GTGACGACGCGATACCGCCGGTGTCCAGCGGACGCCCCGACCGATCAGCCAGTCTGTAC
 CCGGTGTGGTCCCGGCGAAGAACGACGAGACACACGTTCTGTCGCGTGGCGGTTT
 GCGGTGCCGTACGGCGTAACCGATCCGGGCGTCCCGCAGGACCTCCCGTCCAGCAAC
 GGCAGTTCGTGATCTCGAATATGCGGCATTCCACCGCTGACCTCCTTGTTCGATCCCC
 CGGACAACAGGTGCGTCTG GCCGGAGACTCAGAGCCAGTTGGGGCGGATCTCGGTGGCC

CACAGCTCCAGGCTGCGCAGCTGGACATCGTGCGGGATCAGCCCGGAGTACTGGCACTGG
 AGCAGATACTCCGGATCGTGCCGCTCCACCAGCTTCTCGATCATGCGGTGATGTCGTCC
 GGGGTGCCGACCCACTCCAGCCCCGGTGCACCAGGCTCTGTAGTCCGAGCCGATCGGA
 CCCGTCTCGCCGGTGCAGCGCAGCGCTCGGTGAAGCCATGGGGCCGAACCACTTCTCG
 5 AAGATGAAGCCGCCCGCGGGACCCAGTGGTGGGCCTCGCCGGAGTCCCGGGAGACC
 AGGACGTCCTTCATCACCCGACCCGCTCGCCCCGCGCAGGGTGGCGTGGCCCGCGCC
 TCGGCCTCCTCCCGGTAGATGTCCATCAGCCGGGCGACGATCTGGTCTGCTGGTGTTCATC
 AGGATCGGCACCCACGCCCTCCCGGGCACAGAACCAGGACGTGTCTCACTGAAGCTGAAC
 GGCTGGAAGACGGGCGGGTGGGGGCGCTGGTAGGGCTTGGGCGCGATGCCACCTCGCGG
 10 ATGACGCCGTTCTCGTCGAGGCCCGCGCGTAGCGGCGCACCGCCTCGTAGGGGAACCTCC
 AGGTCCGGCACCAGGATCGTCCACTGCTCCCCGAGTGGGTGAACGTCTCGGTCTCCAC
 CGCTTCTTGATGATCTCCAGTGCTCTCGAAGAGGGCACGATTGCGCCGGTCCCGCTCC
 GCGGCTCGGACAGGGTGCCGCGACCCCGTACACCTGCCCATGATGTGCGCCAGCGC
 TTCTGGAACCCGCGCGGATCCCGACGAAGGCGCGGCCCGGGTCATGTGGTCGAGCATC
 15 GCCAGATCTCGGCCAGCCGACGCGGATTGTGCAGCGGACGAGCTTGGCCATCTGGCCG
 ACCCGGATGTGCGGGTCTGCATGCCGAGGTAGAGCCCGAGCATGATCGGGTGTGTGGAG
 ACCTCGAAACCTCGGTGTGGAAGTGGTGCTCGGTGAAGGACAGTCCCCAGTAGCCGAGT
 TCGTCGGCCGCTGCGCCTGCGGGTGGCTGCGGAGCATGTTCTGGTAGTTCTGCGGA
 TTGACCCCGCCATACCCGCTGGACCTGCGCATGACTGCCGACCGTTGGCAGATAGAAG
 20 AGAATGGACTTCACCTGGCTCCTCCGGTTCGCGGCGCCCTCCATTGACGTGCGCCGAAA
 GCGGCTCGACCGTCCCACTCCGCCCTTGAGTTCCGTCTGACGCCGCGCCAGTCCGCGGGC
 CGTCCGCGGGGTGCCCGCGGGGTCCGACCCGCGGACGGCACGGCGCGCACCGCGCG
 CGCGGCGCTTCGGGGCACCGGGTTCGACGGGTGCTCAGCGGGACGTCCAACGGAAGGCA
 AGCCCCGCTACCCAGCTTGGTCAAGGCGCTCATCGCCATTCCCTGAGGAGTCCCGCCTT
 25 GACCACAGCAATCTCCGCGCTCCCGACCGTGCCCGGCTCCGGACTCGAAGCACTGGACCG
 TGCCACCCCTCATCCACCCACCCCTCTCCGAAACACCGCGGAACGGATCGTGCTGACCTC
 GGGGTCCGGCAGCCGGGTCCGCGACACCGACGGCCGGGAGTACCTGGACGCGAGCGCGT
 CCTCGGGGTGACCCAGGTGGGCCACGGCCGGGCGAGCTGGCCCGGTTCGCGCCGAGCA
 GATGGCTCCGCTGGAGTACTTCCACACCTGGGGGACGATCAGCAACGACCGGGCGGTGGA
 30 GCTGGCGGCACGGCTGGTGGGGCTGAGCCCGGAGCCGCTGACCCGCGTCTACTTCACCAG
 CGGCGGGGCGGAGGGCAACGAGATCGCCCTGCGGATGGCCCGGTCTACCACCACCGGCG
 CGGGGAGTCCGCCCCGTACCTGGATACTCTCCCGCCGGTCGGCCTACCACGGCGTCGGATA
 CGGCAGCGGCGGCGTCAACGGCTTCCCGCCTACCACAGGGCTTCGGCCCCCTCCCTCCC
 GGACGTGCACTTCTGACCCCGCGCAGCCCTACCGCCGGGAGCTGTTGCGCCGTTCCGA
 35 CGTACCGCACTTCTGCCCTCGCCGAACGCGCGAGACCATCGACCGGATCGGCCGGAGCG
 GATCGCGCGGATGATCGGCGAGCCGATCATGGGCGCGGTTCGGCGCCGCGGCCCGCCGC
 CGACTACTGGCCCCGGGTCCCGGAGCTGCTGCACTCCTACGGCATCCTGCTGATCTCCGA
 CGAGGTGATCACGGGGTACGGGCGCACCGGGCACTGGTTCGCCCGCGACCACTTCGGCGT
 40 GGTCCCGGACATCATGGTCACCGCCAAGGGCATCACCTCGGGTATGTGCCGACGGCGC
 CGTCCCTGACCGAGGCGGTTCGCCGAGAGGTCTCGGCGACAGGGCTTCCCGCGGG
 CTTACCTACAGCGGCCATGCCACGGCTGCGCGGTGGCCCTGGCCAACCTGGACATCAT
 CGAGCGCGAGAATCTGCTCGACAACGCCAGCACCGTTCGGCGCTACCTGGGCAACCGCT
 GGCCGAGCTGAGCGATCTGCCGATCGTGGGGACGTCCGGCAGACCGGTCTGATGCTCGG
 45 TGTCGAACTGGTTCGCCGACCGCGGAACCCGGGAGCCGCTGCCGGGCGCGCGCTCGCCGA
 GGCCCTGCGCGAGCGGCGGCGATCCTGCTGCGCGCCAACGGCAACGCCCTCATCGTCAA
 CCCCCGCTGATCTTACCCAGGAAGACGCCGACGAACTCGTGGCGGGCTGCGCTCCGT
 ACTCGCCCGCACCAAGGCCGACGGCCGGGTGCTCTGACCCCTTGGCCCTCCCGGCCCG
 ACCGGGGCACCAACCCCGCCGACCCCGAGCGCAAAAGACCCCTCTGCCTGCGTTTCCGC
 AGGTCAAGGGGTCTGGTGCAGTGGAGCCTAGGGGAGTGAACCCCTGACATCTGCCATG
 50 CAAAGACAGCGCTCTACCAACTGAGCTAAGGCCCGAAGCGACAGAACGGCCCTGGACTG
 CTCCGTCCCGGCCACTGCCGAGACAGAGTACCGGGTGTTCGGGTGATCCTCCAAAC
 ATTGAGGTCTCCCGGTGGGCGACCACTCTCCGTAAGATGCTCGACGTGGTTTCGACGACG
 GAAGCCCGCTTGGGGAAGCGATGGGGAGACGCGCATGGACGCCGCTCAGCAGGAGACGAC
 CGCAAGAGCCCGGAGCTACAGCGAAGCTGGTACGGGGAGCCCTGGGGGCGCTGTTCGG
 55 CAGGCTGATAGCAGTCTGGGGCTGAACAGGCGCGTCTCGCGCGGTGCTGGGCCTCTC
 CGCCCCATGCTCTCCAGCTCATGAGCGGCCAGCGGGCCAAGATCGGCAACCCGGCCGT
 GGTCCAACGGGTCCAGGCGCTCCAGGAGTTGGCCGACAGGTGGCCGACGGCAGCGTCAG
 CGCGGTGGAGGCCACCGACCGCATGGAGGAGATCAAGAAGTCGAGGGAGGCTCCGTCTC
 GACCGCAACAGCCAGACCAACAGCTCGGGGGCGCGACCGTCCCGCGGGTCTGTCG
 60 GGAGATCCAGTCTGCTGCGGTCCGTGTCCGCCGCGGGGACATCATCGACGCGGCGAA
 CTCCCTCGCCCCGACCCATCCGGAGCTGGCAGAGTTCCTGCGGGTGTACGGGGCGGGCG
 CACCGCGGACGCGTGGCGCACTACGAGTCCCACAGAGCTGACGACCGAGGCGCGCCCC
 GGAACGGACAGAGCCTCATGAGGACGGGGAGCGGACGCGGCACCATGGGTGAGGTCTT
 CGCCGGCCGGTACGAGCTGGTTCGACCCGATCGGACGCGGAGGGGTTCGGCGGGTCTGGCG
 65 CGCTAGGGACACCGGCGCGCGCTATGTGGCGGCCAAGGTGCTCCAGCAGAGCGACGC
 GCACCTGGTCTGCGCTTCGTCCGCGAGCAGGCCCTGCGGATCGACCATCCCCATGTCCT
 GGCCCGCGGAGCTGGGCGCGGACGACGCAAGTCTCTTACCATGGATCTCGTGGG
 CGGCGGATCACTCGCGACGTGATCGGCGACTACGGCCGCTCCCGCGCGCTATGTGTG

CGCCCTGCTGGACCAACTCCTCTCCGGGCTCGCCGCGGTGCACGCCGAGGGCGTGGTGCA
 CCGCGACATCAAACCGGGCGAACATCCTGATGGAGGCCACGGGACGGGCGCCCCATCT
 GCGCCTGTCCGACTTCGGCATCTCCATGCGCAAGGGCGAGCCCCGGCTGACCGAGACCAA
 CTATGTCTGTGGTACGCCCCGGTTACTTCGCCCCGAGCAGGTGAGGGCGCGGAGCCGGA
 5 CTTCCCCGCCGATCTCTTCGCCGTGCGCCTGGTTCGCCCTCTATCTGCTGGAGGGTCAGAA
 ACCCGACACCAAGGCCCTGGTGGACTTCTTCACCGCCCATGGACCCCCGGTGTCTCCCG
 GGGGATACCGGAGCCGCTGTGGCAGGTGCTCGCGGGGTGATCCAGCCCGACCCCGCCGC
 CCGGTTCCGTACGCGACGGGGGCCGGAAGGCCCTCGCCGCCCGCTGGAAGTCTTCC
 CGAGAGCGGCCCGACGACGAACCGGTGGAGATATTGACCAACTGGGCCCGCTGCCGCC
 10 GGGGTTTCGGCCCCCGCGGCCCGAGAACACGCCGCCCTCCGGTCTGCTGCGCTCGCGCGG
 CTCCGGTACC

SEQ ID NO:18 orf2par reverse complement

ATGGCCACCACGACCGGAAAGCCATGCTGGAACGTTTACCAGTACGGTGTGACCATGTATTGCGCGTCTGTCG
 15 GCCGGGAGGCGTCCGCCATTCTCTTCGACGAGGTGGAAGACTCGACTTCGTCTGACCCGGCAGAGTTACCCGC
 CGGGGTGATGGCGGACGTCTCGCCCCGATACCAACCGCCCCAGGCGTGCTTCGCGACCCGGGGCCCCGGCATG
 ACCAACCTGGCCACCGCGTCCGCCCTCCGCCCTGGACCGCAGCTCGGTTCATCGCGTGGCCGCGCAGTCCGAGT
 CGTACGACTGCTACCCCAACGTACCCACCAAGTGCCTGGACAGCACCGCCGTGATGGGCCGCTGACCAAGTTTCA
 CGTCCAGCTCGAACCGCGGCGAGGACATCGTCAACCTCGTCGACAGCGCCGTCTCAACAGCCGATCGAGCCCGTG
 20 GGTCCCAGCTTCATCAGCTGCGCGTTCGACCTCTCGGCGCCGAGCTGAACGGCACCCCGACCGACGCCCCCTGG
 TCCGGGCCACCGCCACCCACGCCCTGGACGCCGACTGGCGCGCCCGCTCGACGAGGCGCTGAGCTGGTGCGCGA
 GGCCGAGAACCCCTCTCGTCTGTCGTTAGCGCCGTTCATCGCGCGGGGGCGTTCGACGCCCTGCGCGCCCTCGCC
 GAGCGGCTGAACATCCCGTCTGTCACCACTACACCGCAAGGGCGTCTGCGCGACGACACCCGCTCAACTACG
 CGCGCATCAGCGGCTACATGGACGGCATTCTCGGCACCCGGCCCTCGACGAGATCTTCGGCCCCGCGACCTCT
 25 CTTGGCGATCGGCTACGACTACGCGGAGACTCGCCCTCGGCGCCCTCCATGTGGACGCGGGGCCGGCCAGACCAAGT
 CGGGTTCGCCCCGAGGTCAACCCGATCCCGGAGCTGTTCCGCGCGGACATCGACATCGTACCAACGTTCGCCGAAT
 TCGTACCCGCGTTCGACGACGCGACCTCGGGCCTCGCCCCAAGACCCGGCAGACCTCAGCGCCCTGCGCGCCG
 CGTTCGCCGAATTCTCGCGACCCCGAGTACGAGGACGGCATGCGGGTCCACAGGTGATCGACTGCATGAAC
 TCCGTCTCGACAACGGCACCTTCGTGAGCGACATCGGCTTCTTCGCCACTACGGCGTGTCTTCGCCAAGTCCG
 30 ACCAGCGTACGGATTCTCACCTCCGCGGCTGCTCCAGTTCGGCTACGGACTGCCCGCCGATGGCCCGCCCA
 GATCGCCCGGCCCGCGGCGCCGTCTTCTCATCGCGGCGACGGCGGCTTCCACTCCAACAGCGCGGACATCGAG
 ACGGCCGTGCGCTGGGCTGCGGATCGTTCATGGTCTGTCGTCACAACGACCGCAACGGCCTGATCGAGCTGTACC
 AGAACCTCGGACACCGCGCTCCACGCCCCCGCGTTCGGTTCGGAAGCGTTCGACTTCGTCCAGTTCGCGGAGGC
 CAACGGCTGCGAGGCGTCCGCGCCACCGACCGCACCTCGTGTGCGCGCCCTCACCAAGGGCGCGGACTCGGC
 35 CGCCCGTTCTGATCGAGGTACCGTGGCCTACGACTTCCAGTCCGGCGGTTTCGCGGCCCTGGCCATCTGA

SEQ ID NO:19 orf3par reverse complement

ATGCCCGGCCCGACCTCGTGTACGGATTCCGGGTGCGCATCGGCACCGAGGGCGCGCCCGGGCGGGCCCCGGCG
 40 GTCACTCCGAACCCGGCAGCGCACCCCGCTTCGCCGTCCGCGGGACCCATGTCCCGTGCACGACGGCACCGCGTA
 CCCGCTCTGGAGCGGAACGGCCGTGACCTGGGCGGTCCGCCCGTCTGGTTCGCGACGGCCAGGTCCGGCTGCTC
 CTGGCGGGCGAGCTGTACAACCGCGCCGAGCTGACCGGAGCGCTCGGCGGCTCCTCTGCCGCCCTCGGCGACGCCG
 AACTGCTGTGGCCGCTGGCGGCTGGGGCCCCGGGCGCTTCGGCTCCTGAACGGACGGTTCGCGCGCACTGCT
 CACCGACGCTCCACCGCGCGACCGTTCGCGGCCACCGACCGCGGTTTCGGTACCGCTGTGGTTCGCGCGCGGAC
 45 GTGACGGGGCTGAGCGCCGCCACCGAGGCGAAGACCTGGCGCAGGACCGGGCGCGCGCTGGGCTGTCCGGCA
 CCCACACCCCGCGGGGGCGCGGGCGTTCGCCGGTCCCCGCGGGACCGCCCTCTGCTGCACGGAGTTCGCGCGG
 TCCGACATACCGCCAGGGCGGTCCGCACCTGGACACCCCGCTCTCCGGGCGCTGCCCGGCAACGGGAGGCGG
 TGGACCTGGTTCGGCGAACGCTTCGCCACCGCGGTTCGCCACCGGCTGCGCGGCGGGAGGCGGCCCGCCACCGTCT
 CCTGTCCGGCGGATCGACTTCGGGGGAGTCCGCCCCACACCGCGGCCCTGGCACCCGGGACCGTCCGTGTGCG
 50 ATGGGACCGAGGTGTCCGACGAGTTCGACGCGGCCCGCTCGGTTCGCCGTCCACTGGGCACCGCGCACAGCGAGA
 TCCGGCTCCACTCGGCCGAACTCGTCAGGGAAGTGCCTGGGCGGTTCGCCCGCGCGGAGATCACCGACCCACGGT
 CCTGGAGTACCTGCTGCCGTCTGTCGCCCTTACCGGCGGCTCGACACCGGGCGGCTCCGCATCTCACCGGGTAC
 GCGCGGACATCCCGCTCGGCGGTATGCACCGGCGCACGGCTCGCTCTGGTCCCTCGACGACGAGATCGCGGGCG
 ACATGGCGGGCTTCGACGGCTCAACGAGATGTCCCCGTCTTCGCGGGCATCGCCGGGAAGTGGACACCCACCC
 55 GTACTGGGACCGCGCGGTCTGACGCGCTGGTCTCCCTCGAACCCGGGCTCAAACGCCGGCGGGGACCGACAAG
 TGGGTGTTCGGGAGGCCCTCTCCGGCTGTGCCCCGCGAGACCGTGGCCCGCCCCAAGCTGGGCATCCAGGAG
 GGTCCGGCACCAACAGCGGTGGACCGGACTGCTCTCGCCGAAGGGATCCGGCGCGACGAGGTGACGCGCTCAA
 GGGCGCATGGCACGGCGCTGTACGACGCGGTGGTTCATCGACAGGTGCCCGCGGAGGACGTGGAATTCGGCGAG
 ACGGTGCGGCGCTCCGTGACGCGGTGCGCAGGCTCAGGCTCCAGGCGGGTGGTGGTATGA

60 SEQ ID NO:20 orf4par reverse complement

GTGTCCACCGCGTCTCCCCGCGTACGCCCAACGGGCGACCTTCATGCGGCTGCGCCACGGGCCCGACCCGATCG
 GCCATGACGTGGTGGTCTGCGCGCCCCGTACGACGAGGACACAGCTACCGGCCCGCGCGCGGTTTCGCGCGCGG
 CGCCATCCCGGACGAGTCCAGCCTGATCCACGGCGTCCGATCGACCGGGGCCAGGGGTCTTCGACCGGATCGAC
 GTGGTTCGACGGGGCGACATCGACCTCAGCCCTTCTCGATGGACCTGGCGATGGACACCGCGACGGTTCGCGCTGA
 65 CCCGGTCTTGAACGCAACGACGCGTTCCTGATGCTGGGCGGGGACCACTCGCTCTCCCTGGCGGCCCTGCGCGC
 CGTGCACGCCCGCCACGGCCGGTTCGCCGTCTGACCTGGACGCGCACAGCGACACCAACCCACCGTCTACGGC
 GGCACCTACCAACAGGACCCCTTCCGCTGGGCCATCGAAGAGGGCCTGGTGGACCCGGAGCGCTGGTCCAGG

TCGGCATCCGCGGCCACAATCCGCGGCCCGACTCCCTGGACTACGCGCGCGGGCACGGCGTCAGCATCGTCACCGC
CGCCGACTTACCCGCGCGCTCACC GCGCGGCATCGCCGAGCAGATCCGCGCGCACCGTCGGCGGCCTGCCGCTGTAC
GTCTCCGTCGACATCGACGTCGTCGACCCGCGGTACGCCCCGGGCACCGGCACACCGCCCCCGCGGGCTGTCTT
CGCGCGAGGTGCTGACCTGCTCGACGTGGTGGGCGAGCTCAGGCCCGTCGGCTTCGACGTGGTTCGAGGTGTCCCC
5 GCGGTACGACCCGTCGGGGATCACTCCCTGCTGGCGCGGAGATCGGGGCCGAAGTCTCTACAGTACGCCCGC
GCCACCACGTCGCGCGCGTCGGCACCGGTGGACTCTCCCTGCCACCGGGGGCGGGCGGACGACGCCGAGAACG
CCGAGAACCGCGGTGGACGCGGTGGACGCCGAGAGCGCGTGGACTTCGCCGGGCAGCGGTGGGGGTAG

SEQ ID NO:21 cvm6 Polypeptide

10 VPGSGLEALDRATLIHPTLSGNTAERIVLTSGSGSRVRDTDGREYLDASAVLGVTQVGHGRAELARVAEQMARLEY
FHTWGTISNDRAVELAARLVGLSPEPLTRVYFTSGGAEGNEIALRMARLYHHRRGESARTWILSRRSAYHGVGYGSG
GVTGFPAHQGFPGPSLPDVFLLTPQPYRRELFAGSDVTFCLAELETIDRIGPERIAAMIGEPIMGAVGAAAPPA
DYWPRVAELLHSYGILLISDEVITGYGRTGHWFAADHFGVVPDIMVTAKGITSYVPHGAVLTTEAVADEVVGDQGF
15 PAGFTYSGHATACAVLANLDI IERENLLDNASTVGAYLGKRLAELS DLPVGDVDRQTGLMLGVELVARGTREPLPG
AAVAEALRERAGILLRANGNALIVNPLIFTQEDADELVAGLRSLARTRPDGRVL

SEQ ID NO:22 cvm3 Polypeptide

20 VTRPPGLSAHTGVS VSGSLLRRVAGHYPTGVVLVTGPAAEPGQPPPMVVGTFSTVSLDPVLVGF LPARSSTTWPR
LRAAGRFCVNVLGADQGPVCRSFAGGDPGRWEVPYRTTATGSPVLLDALAWFDCEVAGETEAGDHWFTVGAVRDLG
VIREGSPLVFLRGDYGHWAGGGSGRAGRRAVCPV

SEQ ID NO:23 orf6par Polypeptide

25 MRASSPRGFRVHHGHAGIRGSHADLAVIASDVPAAVGAVFTRSRFAAPSVLLSRDAVADGIARGVVVLSGNANAGT
GPRGYEDAAEVRHLVAGIVDCDERDVLIASTGPVGERYPMSRVRAHLRAVRGFLPGADFDGAAAVALGTAGARPTI
RRARCGDATLIGVAKPGTGPAEQDDRSTLAFFCTDAQVSPVVLDDIFRRVADRAFHGLGFGADASTGDTAAVLAN
GLAGRVLDLVAFEQVLGALALDLVRDVVRD SGCGGALVTVRVTGAHDTEQAGRVGRAVVDAPSLRAAVHGPAPDWAP
VAAVAGGHGDEGPGRSPGRITIRVGGREVFPAPDRARPDAVTAYPHGGEVTVHIDLGVPGRAPGAFTVHGCDLLA
GYPRLGAGRAV.

SEQ ID NO:24 orf4par Polypeptide

30 VSTAVSPRYAQPATFMRLRHRPDPIGHDVVVVGAPYDGGTSYRPGARFAPRAIRHESSLIHGVGIDRGPVGFDRID
VVDGGDIDLSPFMDLAMDTATVALTRLLERND AFLMLGGDHSLSLAALRAVHARHGRVAVLHLDAHSDTNPPVYG
GTYHHGT PFRWAEELVDPERLVQVGIRGHNPRPDSLDYARGHGVSI VTAADFTRRSRPGIAEQIRRTVGGGLPLY
35 VSVDIDVVDPAYAPGTGT PAPGGLSSREVLTLLDVVGQLRPVGF DVVEVSPAYDPSGITSLLAAEIGAELLYQYAR
ATTSPASAPVDSPLFPGAADDAENAENAVDAVDAESA VDFAGQRWG.

SEQ ID NO:25 orf3par Polypeptide

40 MPGPDLVYGFVRIGTEGRPGGGPGGHSEPGSAPRFAVRGTHVPVHDGTAYPLWSGTAVTLGRPPVLVADGQVRL
LAGELYNRAELTGALGGSSAALGDAELLLAAWRRWGPGA FRLNNGRFAALLTDASTGATVAATDHAGSVPLWLRAD
VTGLSAATEAKTLAHEPGRPLGLSGHTAPGAAGVCRVPAGTALLHGVGGS DITARAVRTWTPPLSRALPGEREA
VDLVGERLATAVRTRLRGGEAAPT VVLSGGIDSGGVAHTAALAPGTRSVSMGTEVSDEFDAARSVAVHLGTAHSE
IRLHSAELVREL PWAVAAAEITDPTVLEYLLPLVALYRRLDTGPLRILTGYGADIPLGGMHRR TASLWSLDDEIAG
DMAGFDGLNEMSPVLAGIAGKWTTHPYWDRAVL DALVSLPEPLKRRRGTDKWLRLQALSGLLPAETVARPKLGIHE
45 GSGTTSAWTGLLLAEGIRRDEVTAVKGAMARRLYDAVVIDTVPPEDVDFGETVRRSVDVAVRRLRLQGRVVV.

SEQ ID NO:26 orf2par Polypeptide

50 MATTTAKAMLERLHQYGVDFHVFVVGREASAILFDEVEGLDFVLTRHEFTAGVMADV LARITNRPQACFATLGP
TNLATGVATSALDRSSVIALAAQSESYDCYPNVTHQCLDSTAVMGPLTKFSVQLERGEDIVNLVDSAVLNSRIE
GPSFISLPVDLLGAELNGTPTDAPLVRATATHALDADWRARLDEAAELVREANPLLVGSAVIRAGAVDALRALA
ERLNI PVVTYTTAKGVLPHDHP LNYGAISGYMDGILGHPALDEIFGPADLLAIGYDYAEDLRPSMWTRGRAKTTV
RVAVEVNP IPELFRADIDIVTNVAEFVTALDDATSG LAPKTRHDL SALRARVAEF LADPTEYEDGMRVHQVIDCMN
SVLDNGTFVSDIGFFRHYGVLF AKSDQPYGFLT SAGCSSFGYGLPAAMAAQIARPGEPVFLIAGDGGFHSNSADIE
TAVRLGLPIVMVVNDRNGLIELYQNLGHQRSHAPAVGFGSVDFVQLAEANGCEAVRATDRTSLLAALT KGAGLG
55 RPFLIEVPVAYDFQSGGFAALAI